

1                   **KEY QUESTIONS FOR MODELLING COVID-19 EXIT STRATEGIES**

2

3                   **AUTHORS**

4                   Robin N. Thompson<sup>1,2,3,\*</sup>, T. Déirdre Hollingsworth<sup>4</sup>, Valerie Isham<sup>5</sup>, Daniel Arribas-Bel<sup>6,7</sup>, Ben  
5                   Ashby<sup>8</sup>, Tom Britton<sup>9</sup>, Peter Challenor<sup>10</sup>, Lauren H. K. Chappell<sup>11</sup>, Hannah Clapham<sup>12</sup>, Nik J.  
6                   Cunniffe<sup>13</sup>, A. Philip Dawid<sup>14</sup>, Christl A. Donnelly<sup>15,16</sup>, Rosalind M. Eggo<sup>3</sup>, Sebastian Funk<sup>3</sup>,  
7                   Nigel Gilbert<sup>17</sup>, Julia R. Gog<sup>18</sup>, Paul Glendinning<sup>19</sup>, William S. Hart<sup>1</sup>, Hans Heesterbeek<sup>20</sup>,  
8                   Thomas House<sup>21,22</sup>, Matt Keeling<sup>23</sup>, István Z. Kiss<sup>24</sup>, Mirjam E. Kretzschmar<sup>25</sup>, Alun L. Lloyd<sup>26</sup>,  
9                   Emma S. McBryde<sup>27</sup>, James M. McCaw<sup>28</sup>, Joel C. Miller<sup>29</sup>, Trevelyan J. McKinley<sup>30</sup>, Martina  
10                  Morris<sup>31</sup>, Philip D. O'Neill<sup>32</sup>, Carl A. B. Pearson<sup>3,33</sup>, Kris V. Parag<sup>16</sup>, Lorenzo Pellis<sup>19</sup>, Juliet R.  
11                  C. Pulliam<sup>33</sup>, Joshua V. Ross<sup>34</sup>, Michael J. Tildesley<sup>23</sup>, Gianpaolo Scalia Tomba<sup>35</sup>, Bernard W.  
12                  Silverman<sup>15,36</sup>, Claudio J. Struchiner<sup>37</sup>, Pieter Trapman<sup>9</sup>, Cerian R. Webb<sup>13</sup>, Denis Mollison<sup>38</sup>,  
13                  Olivier Restif<sup>39</sup>

14

15                  **AFFILIATIONS**

16                  <sup>1</sup>Mathematical Institute, University of Oxford, Woodstock Road, OX2 6GG Oxford, UK  
17                  <sup>2</sup>Christ Church, University of Oxford, St Aldates, Oxford OX1 1DP, UK  
18                  <sup>3</sup>Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical  
19                  Medicine, Keppel Street, London WC1E 7HT, UK  
20                  <sup>4</sup>Big Data Institute, University of Oxford, Old Road Campus, Oxford OX3 7LF, UK  
21                  <sup>5</sup>Department of Statistical Science, University College London, Gower Street, London WC1E  
22                  6BT, UK  
23                  <sup>6</sup>School of Environmental Sciences, University of Liverpool, Brownlow Street, Liverpool L3 5DA,  
24                  UK  
25                  <sup>7</sup>The Alan Turing Institute, British Library, 96 Euston Road, London NW1 2DB, UK  
26                  <sup>8</sup>Department of Mathematical Sciences, University of Bath, North Road, Bath BA2 7AY, UK  
27                  <sup>9</sup>Department of Mathematics, Stockholm University, Kräftriket, 106 91 Stockholm, Sweden  
28                  <sup>10</sup>College of Engineering, Mathematical and Physical Sciences, University of Exeter, Exeter EX4  
29                  4QE, UK  
30                  <sup>11</sup>Department of Plant Sciences, University of Oxford, South Parks Road, Oxford, OX1 3RB, UK  
31                  <sup>12</sup>Saw Swee Hock School of Public Health, National University of Singapore, 12 Science Drive,  
32                  Singapore 117549, Singapore  
33                  <sup>13</sup>Department of Plant Sciences, University of Cambridge, Downing Street, Cambridge, CB2 3EA,  
34                  UK  
35                  <sup>14</sup>Statistical Laboratory, University of Cambridge, Wilberforce Road, Cambridge, CB3 0WB, UK  
36                  <sup>15</sup>Department of Statistics, University of Oxford, St Giles', Oxford OX1 3LB, UK  
37                  <sup>16</sup>Department of Infectious Disease Epidemiology, Imperial College, Norfolk Place, London W2  
38                  1PG, UK  
39                  <sup>17</sup>Department of Sociology, University of Surrey, Stag Hill, Guildford GU2 7XH, UK  
40                  <sup>18</sup>Centre for Mathematical Sciences, University of Cambridge, Wilberforce Road, Cambridge CB3  
41                  0WA, UK

\*Correspondence to: robin.thompson@chch.ox.ac.uk

<http://mc.manuscriptcentral.com/prsb>

- 42 <sup>19</sup>Department of Mathematics, University of Manchester, Oxford Road, Manchester M13 9PL, UK  
43 <sup>20</sup>Department of Population Health Sciences, Utrecht University, Yalelaan, 3584 CL Utrecht, The  
44 Netherlands  
45 <sup>21</sup>IBM Research, The Hartree Centre, Daresbury, Warrington WA4 4AD, UK  
46 <sup>22</sup>Mathematics Institute, University of Warwick, Gibbet Hill Campus, Coventry CV4 7AL, UK  
47 <sup>23</sup>Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, School of  
48 Life Sciences and Mathematics Institute, University of Warwick, Gibbet Hill Road, Coventry CV4  
49 7AL, UK  
50 <sup>24</sup>School of Mathematical and Physical Sciences, University of Sussex, Falmer, Brighton BN1  
51 9QH, UK  
52 <sup>25</sup>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht  
53 University, Heidelberglaan 100, 3584CX Utrecht, The Netherlands  
54 <sup>26</sup>Department of Mathematics, North Carolina State University, Stinson Drive, Raleigh, NC 27607,  
55 USA  
56 <sup>27</sup>Australian Institute of Tropical Health and Medicine, James Cook University, Townsville,  
57 Queensland 4811, Australia  
58 <sup>28</sup>School of Mathematics and Statistics, University of Melbourne, Carlton, Victoria 3010, Australia  
59 <sup>29</sup>Department of Mathematics and Statistics, La Trobe University, Bundoora, Victoria 3086,  
60 Australia  
61 <sup>30</sup>College of Medicine and Health, University of Exeter, Barrack Road, Exeter EX2 5DW, UK  
62 <sup>31</sup>Department of Sociology, University of Washington, Savery Hall, Seattle, Washington 98195,  
63 USA  
64 <sup>32</sup>School of Mathematical Sciences, University of Nottingham, University Park, Nottingham NG7  
65 2RD, UK  
66 <sup>33</sup>South African DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis  
67 (SACEMA), Stellenbosch University, Jonkershoek Road, Stellenbosch 7600, South Africa  
68 <sup>34</sup>School of Mathematical Sciences, University of Adelaide, South Australia 5005, Australia  
69 <sup>35</sup>Department of Mathematics, University of Rome Tor Vergata, 00133 Rome, Italy  
70 <sup>36</sup>Rights Lab, University of Nottingham, Highfield House, Nottingham NG7 2RD, UK  
71 <sup>37</sup>Escola de Matemática Aplicada, Fundação Getúlio Vargas, Praia de Botafogo, 190 Rio de  
72 Janeiro, Brazil  
73 <sup>38</sup>Department of Actuarial Mathematics and Statistics, Heriot-Watt University, Edinburgh EH14  
74 4AS, UK  
75 <sup>39</sup>Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge  
76 CB3 0ES, UK

**77 ABSTRACT**

78 Combinations of intense non-pharmaceutical interventions (“lockdowns”) were introduced in  
79 countries worldwide to reduce SARS-CoV-2 transmission. Many governments have begun to  
80 implement lockdown exit strategies that allow restrictions to be relaxed while attempting to  
81 control the risk of a surge in cases. Mathematical modelling has played a central role in guiding  
82 interventions, but the challenge of designing optimal exit strategies in the face of ongoing  
83 transmission is unprecedented. Here, we report discussions from the Isaac Newton Institute  
84 “Models for an exit strategy” workshop (11-15 May 2020). A diverse community of modellers  
85 who are providing evidence to governments worldwide were asked to identify the main questions  
86 that, if answered, will allow for more accurate predictions of the effects of different exit  
87 strategies. Based on these questions, we propose a roadmap to facilitate the development of  
88 reliable models to guide exit strategies. The roadmap requires a global collaborative effort from  
89 the scientific community and policy-makers, and is made up of three parts: i) improve estimation  
90 of key epidemiological parameters; ii) understand sources of heterogeneity in populations; iii)  
91 focus on requirements for data collection, particularly in Low-to-Middle-Income countries. This  
92 will provide important information for planning exit strategies that balance socio-economic  
93 benefits with public health.

94

**95 KEYWORDS**

96 COVID-19; SARS-CoV-2; exit strategy; mathematical modelling; epidemic control; uncertainty

## 97 INTRODUCTION

98 As of 21 July 2020, the coronavirus disease 2019 (COVID-19) pandemic has been responsible  
99 for more than 14 million reported cases worldwide, including over 613,000 deaths. Mathematical  
100 modelling is playing an important role in guiding interventions to reduce the spread of Severe  
101 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Although the impact of the virus  
102 has varied significantly across the world, and different countries have taken different approaches  
103 to counter the pandemic, many national governments introduced packages of intense non-  
104 pharmaceutical interventions (NPIs), informally known as “lockdowns”. Although the socio-  
105 economic costs (e.g. job losses and potential long-term mental health effects) are yet to be  
106 assessed fully, public health measures have led to substantial reductions in transmission [1–3].  
107 Data from countries such as Sweden and Japan, where epidemics peaked without strict  
108 lockdowns being introduced, will be useful for comparing different approaches and conducting  
109 retrospective cost-benefit analyses.

110

111 As case numbers have either stabilised or declined in many countries, attention has now turned to  
112 the development of strategies that allow restrictions to be lifted [4,5] in order to alleviate the  
113 economic, social and other health costs of lockdowns. However, in countries with active  
114 transmission still occurring, daily disease incidence could increase again quickly, while countries  
115 that have suppressed community transmission successfully face the risk of transmission  
116 reestablishing due to reintroductions. In the absence of a vaccine or sufficient herd immunity to  
117 reduce transmission substantially, COVID-19 exit strategies pose unprecedented challenges to  
118 policy-makers and the scientific community. Given our limited knowledge of this virus, and the  
119 fact that entire packages of interventions were introduced in quick succession in many countries

120 as case numbers increased, it is challenging to estimate the effects of removing individual  
121 measures directly and modelling remains of paramount importance.

122

123 Here, we report discussions from the “Models for an exit strategy” workshop (11-15 May 2020)  
124 that took place online as part of the Isaac Newton Institute’s “Infectious Dynamics of  
125 Pandemics” programme. The Isaac Newton Institute in Cambridge is the UK’s national research  
126 institute for mathematics, and many distinguished scientists (including nine Nobel laureates and  
127 27 Fields Medallists) have attended programmes there. We outline progress to date and open  
128 questions in modelling exit strategies that arose during discussions at the workshop. Most  
129 participants were working actively on COVID-19 at the time of the workshop, often with the aim  
130 of providing evidence to governments, public health authorities and the general public to support  
131 the pandemic response. After four months of intense model development and data analysis, the  
132 workshop gave participants a chance to take stock and openly share their views of the main  
133 challenges they are facing. A range of countries were represented, providing a unique forum to  
134 discuss the different epidemic dynamics and policies around the world. Although the main focus  
135 was on epidemiological models, the interplay with other disciplines formed an integral part of  
136 the discussion. The purpose of this article is twofold: to highlight key knowledge gaps hindering  
137 current predictions and projections, and to provide a roadmap for modellers and other scientists  
138 wishing to make useful contributions to the development of solutions.

139

140 Given that SARS-CoV-2 is a newly discovered virus, the evidence base is changing rapidly. This  
141 makes it challenging to conduct a systematic review of the literature. For that reason, we asked  
142 the large group of researchers at the workshop for their expert opinions on the most important

143 open questions, and relevant literature, that will enable exit strategies to be planned with more  
144 precision. By inviting contributions from representatives of different countries and areas of  
145 expertise (including social scientists, immunologists, infectious disease outbreak modellers and  
146 others), and discussing the expert views raised at the workshop in detail, we sought to reduce  
147 geographic and disciplinary biases. All evidence is summarised here in a policy-neutral manner.


148

149 The questions in this article have been grouped as follows. First, we discuss outstanding  
150 questions for modelling exit strategies that are related to key epidemiological quantities, such as  
151 the reproduction number and herd immunity fraction. We then identify different sources of  
152 heterogeneity underlying SARS-CoV-2 transmission and control, and consider how differences  
153 between hosts and populations across the world should be included in models. Finally, we  
154 discuss current challenges relating to data requirements, focussing on the data that are needed to  
155 resolve current knowledge gaps and how uncertainty in modelling outputs can be communicated  
156 to policy-makers and the wider public. In each case, we outline the most relevant issues,  
157 summarise expert knowledge and propose specific steps towards the development of evidence-  
158 based exit strategies. This leads to the development of a roadmap for future research (Fig 1)  
159 made up of three key steps: i) improve estimation of epidemiological parameters using outbreak  
160 data from different countries; ii) understand heterogeneities within and between populations that  
161 affect virus transmission and interventions; iii) focus on data needs, particularly data collection  
162 and methods for planning exit strategies in Low-to-Middle-Income countries (LMICs) where  
163 data are often lacking. This roadmap is not a linear process: improved understanding of each  
164 aspect of the proposed research will help to inform other requirements. For example, a clearer  
165 understanding of the model resolution required for accurate forecasting (Section 2.1) will inform

166 the data that need to be collected (Section 3), and vice versa. If this roadmap can be followed, it  
 167 will be possible for policy-makers to predict the effects of different potential exit strategies with  
 168 increased precision. This is of clear benefit to global health, allowing exit strategies to be chosen  
 169 that allow interventions to be relaxed while limiting the risk of substantial further transmission.

170

171



172

173 Figure 1. Roadmap of research to facilitate the development of reliable models to guide exit strategies. Three key  
 174 steps are required: i) improve estimates of epidemiological parameters (such as the reproduction number and herd  
 175 immunity fraction) using data from different countries (Sections 1.1-1.4); ii) understand heterogeneities within and  
 176 between populations that affect virus transmission and interventions (Sections 2.1-2.4); iii) focus on data  
 177 requirements for predicting the effects of individual interventions, particularly – but not exclusively – in data limited  
 178 settings such as LMICs (Sections 3.1-3.3). Work in these areas must be conducted concurrently, since feedback will  
 179 arise from the results of the proposed research that will be useful for shaping next steps across the different topics.

## 180 **1 KEY EPIDEMIOLOGICAL QUANTITIES**

### 181 *1.1 HOW CAN VIRAL TRANSMISSIBILITY BE ASSESSED MORE* 182 *ACCURATELY?*

183 The time-dependent reproduction number,  $R(t)$  or  $R_t$ , has emerged as the main quantity used to  
 184 assess the transmissibility of SARS-CoV-2 in real time [6–10]. Within a given population with

185 active virus transmission, the value of  $R(t)$  represents the expected number of secondary cases  
186 generated by someone infected at time  $t$ . If this quantity is and remains below one, then an  
187 ongoing outbreak will eventually fade out. Although easy to understand intuitively, estimating  
188  $R(t)$  from case reports (as opposed to, for example, observing  $R(t)$  in known or inferred  
189 transmission trees [11]) requires the use of mathematical models. As factors such as contact rates  
190 between infectious and susceptible individuals change during an outbreak in response to public  
191 health advice or movement restrictions, the value of  $R(t)$  has been found to respond rapidly. For  
192 example, across the UK, countrywide and regional estimates of  $R(t)$  dropped from  
193 approximately 2.5-4 in mid-March [7,12] to below one after lockdown was introduced [12,13].  
194 One of the criteria in the UK and elsewhere for relaxing the lockdown was for the reproduction  
195 number to decrease to “manageable levels” [14]. Monitoring  $R(t)$ , as well as case numbers, as  
196 individual components of the lockdown are relaxed is critical for understanding whether or not  
197 the outbreak remains under control [15].

198

199 Several mathematical and statistical methods for estimating temporal changes in the reproduction  
200 number have been proposed in the last 20 years. Two popular approaches are the Wallinga–  
201 Teunis method [16] and the Cori method [17,18]. These methods use case notification data along  
202 with an estimate of the serial interval distribution (the times between successive cases in a  
203 transmission chain) to infer the value of  $R(t)$ . Other approaches exist (e.g. based on  
204 compartmental epidemiological models [19]), including those that can be used alongside  
205 different data (e.g. time series of deaths [7,12,20] or phylogenetic data [21–24]).

206

207 Despite this extensive theoretical framework, practical challenges remain when dealing with  
208 real-time reporting. In particular, reproduction number estimates often rely on case notification  
209 data and so are subject to reporting delays between case onset and being recorded. Available data  
210 therefore do not include up-to-date knowledge of current numbers of infections, an issue that can  
211 be addressed using “nowcasting” models [8,12,25]. The serial interval represents the period  
212 between symptom onset times in a transmission chain, rather than between the times at which  
213 cases are recorded. Time series of symptom onset dates, or even infection dates (to be used with  
214 the estimates of the generation interval when inferring  $R(t)$ ), can be estimated from case  
215 notification data using latent variable methods [8,26] or deconvolution methods such as the  
216 Richardson-Lucy deconvolution technique [27,28]. The Richardson-Lucy approach has  
217 previously been applied to infer incidence curves from time series of deaths [29]. These methods,  
218 as well as others that account for reporting delays [30], provide useful avenues to improve the  
219 practical estimation of  $R(t)$  given incomplete data. Furthermore, changes in testing practice (or  
220 capacity to conduct tests) lead to temporal changes in case numbers that cannot be distinguished  
221 easily from changes in transmission. Understanding how accurately and how quickly changes in  
222  $R(t)$  can be inferred in real-time given these challenges is a crucial question.

223

224 A more immediate way to assess temporal changes in the reproduction number that does not  
225 require nowcasting is by observing people's transmission-relevant behaviour directly, e.g.  
226 through contact surveys or mobility data [31]. These methods do, however, come with their own  
227 limitations: because these surveys do not usually collect data on infections, care must be taken in  
228 using them to understand and predict ongoing changes in transmission.

229

230 Other outstanding challenges in assessing variations in  $R(t)$  include the need to understand that  
231 methods tend to be inaccurate when case numbers are low, and the requirement to account for  
232 temporal changes in the serial interval or generation time distribution of the disease [32]. Indeed,  
233 in periods when there are few cases (such as in the “tail” of an epidemic – Section 1.4), there is  
234 little information with which to assess virus transmissibility. Methods for estimating  $R(t)$  that  
235 are based on the assumption that transmissibility is constant within fixed time periods can be  
236 applied with windows of long duration (thereby including more case notification data with which  
237 to estimate  $R(t)$ ) [33,34]. However, this comes at the cost of a loss of sensitivity to temporal  
238 variations in transmissibility. Consequently, when case numbers are low, the methods described  
239 above for tracking transmission-relevant behaviour directly are particularly important. In those  
240 scenarios, the “transmission potential” might be more important than realised transmission [35].

241

242 The effect of population heterogeneity on reproduction number estimates also requires further  
243 investigation, as current estimates of  $R(t)$  tend to be calculated for whole populations (e.g.  
244 countries or regions). Understanding the characteristics of constituent groups contributing to this  
245 value is important to target interventions efficiently with limited resources [36,37]. For this, data  
246 on infections within and between different subpopulations (e.g. infections in care homes and in  
247 the wider population) are needed. As well as between subpopulations, it is also necessary to  
248 ensure that estimates of  $R(t)$  account for heterogeneity in transmission between different  
249 infectious hosts. Such heterogeneity alters the effectiveness of different control measures, and  
250 therefore the predicted disease dynamics when individual interventions are relaxed. For a range  
251 of diseases, a rule of thumb that around 20% of infected individuals are the sources of 80% of  
252 infections has been proposed [37,38]. This is supported by recent evidence for COVID-19, which

253 suggests significant individual-level variation in SARS-CoV-2 transmission [39] with some  
254 transmission events leading to large numbers of new infections.

255

256 Finally, it is well documented that presymptomatic individuals (and, to a lesser extent,  
257 asymptomatic infected individuals - i.e. those who never develop symptoms) can transmit SARS-  
258 CoV-2 [40,41]. For that reason, negative serial intervals may occur when an infected host  
259 displays COVID-19 symptoms before the person who infected them [42,43]. Although methods  
260 for estimating  $R(t)$  with negative serial intervals exist [43,44], the inclusion of presymptomatic  
261 or asymptomatic transmission in publicly available software for estimating  $R(t)$  should be a  
262 priority. Increasing the accuracy of estimates of  $R(t)$  in the ways described here, as well as  
263 supplementing these estimates with other assessments of transmissibility (e.g. estimates of  
264 growth rates of case numbers [45]), is of clear importance. As lockdowns are relaxed, this will  
265 permit a fast determination of whether or not removed interventions are leading to a surge in  
266 cases.

267

## 268 *1.2 WHAT IS THE HERD IMMUNITY THRESHOLD AND WHEN MIGHT WE* 269 *REACH IT?*

270 Herd immunity refers to the accumulation of sufficient immunity in a population through  
271 infection and/or vaccination to prevent further substantial outbreaks. It is a major factor in  
272 determining exit strategies, but data are still very limited. Dynamically, the threshold at which  
273 herd immunity is achieved is the point at which  $R(t)$  (Section 1.1) falls below one for an  
274 otherwise uncontrolled epidemic, resulting in a negative epidemic growth rate. However,  
275 reaching the herd immunity threshold does not mean that the epidemic is over or that there is no

276 risk of further infections. Great care must therefore be taken in communicating this concept to  
277 the public, to ensure continued adherence to public health measures such as social distancing.  
278 Crucially, whether immunity is gained naturally through infection or through random or targeted  
279 vaccination affects the herd immunity threshold, and the threshold depends critically on the  
280 immunological characteristics of the pathogen. Since SARS-CoV-2 is a new virus, its  
281 immunological characteristics - notably the duration and extent to which prior infection confers  
282 protection against future infection, and how these vary across the population - are currently  
283 unknown [46]. Lockdown measures have heavily impacted contact structure and hence the  
284 accumulation of immunity in the population, and are likely to have led to significant  
285 heterogeneity in acquired immunity (e.g. by age, location, workplace). Knowing the extent and  
286 distribution of immunity in the population will help guide optimal exit strategies that have only a  
287 limited risk of a resurgence in infections.

288

289 As interventions are lifted, whether or not  $R(t)$  remains below one depends on the current level  
290 of immunity in the population as well as the specific exit strategy followed. A simple illustration  
291 is to treat the current reproduction number,  $R(t)$ , as a deflation of the original (basic)  
292 reproduction number ( $R_0$ , which is assumed to be greater than one):

293

$$R(t) = (1 - i(t))(1 - p(t))R_0,$$

294 in which  $i(t)$  is the immunity level in the community at time  $t$  and  $p(t)$  is the overall reduction  
295 factor from the control measures that are in place. If  $i(t) > 1 - \frac{1}{R_0}$ , then  $R(t)$  remains below one  
296 even when all interventions are lifted: herd immunity is achieved. However, recent results  
297 [47,48] show that, for heterogeneous populations, herd immunity occurs at a lower immunity  
298 level than  $1 - \frac{1}{R_0}$ . The threshold  $1 - \frac{1}{R_0}$  assumes random vaccination, with immunity distributed

299 uniformly in the community. When immunity is obtained from disease exposure, the more  
300 socially active individuals in the population are over-represented in cases from the early stages of  
301 the epidemic. As a result, the virus preferentially infects individuals with higher numbers of  
302 contacts, thereby acting like a well-targeted vaccine. This reduces the herd immunity threshold.  
303 However, the extent to which heterogeneity in behaviour lowers the herd immunity threshold for  
304 COVID-19 is currently unknown.

305

306 We highlight three key challenges for determining the herd immunity threshold for COVID-19,  
307 and hence for understanding the impact of implementing or lifting control measures in different  
308 populations. First, most of the quantities for calculating the herd immunity threshold are not  
309 known precisely and require careful investigation. For example, determining the immunity level  
310 in a community is far from trivial for a number of reasons: antibody tests may have variable  
311 quality in terms of sensitivity and specificity; it is currently unclear whether or not individuals  
312 with mild or no symptoms acquire immunity or test seropositive; the duration of immunity is  
313 unknown. Second, estimation of  $R_0$ , despite receiving significant attention at the start of the  
314 pandemic, still needs to be refined within and between countries as issues with early case reports  
315 come to light and are addressed. Third, as discussed in Section 2, SARS-CoV-2 does not spread  
316 uniformly through populations [49]. An improved understanding of the main transmission routes,  
317 and which communities are most influential, will help to determine how much lower disease  
318 induced herd immunity is compared to the classical herd immunity threshold  $1 - \frac{1}{R_0}$ .

319

320 To summarise, it is of paramount importance to obtain more accurate estimates of the current  
321 immunity levels in different countries and regions, and to understand more clearly how  
322 population heterogeneity affects virus transmission and the accumulation of immunity.  
323

### 324 *1.3 CAN SEROPREVALENCE SURVEYS PROVIDE INSIGHT INTO HERD* 325 *IMMUNITY AND TRANSMISSION DYNAMICS?*

326 Information about how many people are currently infected and have been infected in the past are  
327 key inputs to formulate exit strategies, monitor the progression of epidemics and identify social  
328 and demographic sources of transmission heterogeneities. Seroprevalence surveys provide a  
329 simple and direct way to estimate the fraction of the population that has been exposed to the  
330 virus but has not been detected by regular surveillance mechanisms [50]. Given the possibility of  
331 mild or asymptomatic infections, which are not typically captured in data describing laboratory-  
332 confirmed cases, seroprevalence surveys have the potential to be particularly useful for tracking  
333 the COVID-19 pandemic [51].  
334

335 Contacts between pathogens and hosts that elicit an immune response can be revealed by the  
336 presence of antibodies. Broadly speaking, there are two major classes of antibody, with rising  
337 concentrations of immunoglobulin M (IgM) preceding the increase in concentration of  
338 immunoglobulin G (IgG). However, for infections by SARS-CoV-2, there is increasing evidence  
339 that IgG and IgM appear concurrently [52]. Most serological assays used for understanding viral  
340 transmission measure concentrations of IgG. Interpretation of a positive result depends on the  
341 availability of detailed knowledge of immune response dynamics and its epidemiological  
342 correspondence to the developmental stage of the pathogen, for example the presence of virus

343 shedding in the case of SARS-CoV-2 [53,54]. Serological surveys are common practice in  
344 infectious disease epidemiology and have been used to estimate the prevalence of carriers of  
345 antibodies, force of infection, and reproduction numbers [55], and in certain circumstances (e.g.  
346 for measles) used to infer population immunity to a pathogen [56]. Unfortunately, single  
347 serological surveys only provide information about the numbers of individuals who are  
348 seropositive at the times the surveys were conducted (as well as information about the  
349 individuals tested, such as their age [57]). Although information about temporal changes in  
350 infections can be obtained by conducting multiple surveys longitudinally [46,58], the precise  
351 timings of infections remain unknown.

352

353 Available tests vary in sensitivity and specificity, which can impact the accuracy of predictions  
354 made using compartmental models if seropositivity is used to assess the proportion of individuals  
355 that are protected from infection or disease. Propagation of uncertainty due to the sensitivity and  
356 specificity of the testing procedures and epidemiological interpretation of the immune response  
357 are areas that require attention. The possible presence of immunologically silent individuals, as  
358 implied by studies of COVID-19 showing that 10–20% of symptomatically infected people have  
359 few or no detectable antibodies [59], adds to the known sources of uncertainty. Ambiguities in  
360 the interpretation of the biological meaning of testing outcomes and limitations of study designs  
361 raise issues related to the identifiability of parameters of interest.

362

363 Many compartmental modelling studies have used data on deaths as the main reliable dataset for  
364 model fitting. The extent to which seroprevalence data could provide an additional useful input  
365 for model calibration, and help in formulating exit strategies, has yet to be ascertained. With the

366 caveats above, one-off or regular assessments of the seroprevalence in the population could be  
367 helpful in understanding transmission of SARS-CoV-2 in different populations.

368

#### 369 *1.4 IS GLOBAL ERADICATION OF SARS-COV-2 A REALISTIC POSSIBILITY?*

370 When  $R_0$  is greater than one, an emerging outbreak will either grow to infect a substantial  
371 proportion of the population or become extinct before it is able to do so [60–64]. If instead  $R_0$  is  
372 less than one, the outbreak will almost certainly become extinct before a substantial proportion  
373 of the population is infected. If new susceptible individuals are introduced into the population  
374 (for example, new susceptible individuals are born), it is possible that that the disease will persist  
375 after its first wave and become endemic [65]. These theoretical results can be extended to  
376 populations with household and network structure [66,67] and scenarios in which  $R_0$  is very  
377 close to one [68].

378

379 Epidemiological theory and data from multiple different diseases indicate that extinction can be a  
380 slow process, often involving a long “tail” of cases with significant random fluctuations (Figure  
381 S1). Long epidemic tails can be driven by factors including spatial heterogeneities, such as  
382 differences in weather in different countries (potentially allowing an outbreak to persist by  
383 surviving in different locations at different times of year) and varying access to treatment in  
384 different locations. Regions or countries that eradicate SARS-CoV-2 successfully might  
385 experience reimportations from elsewhere [69,70], for example the reimportation of the virus to  
386 New Zealand from the UK in June 2020.

387

388 At the global scale, smallpox is the only previously endemic human disease to have been  
389 eradicated, and extinction took many decades of vaccination. Prevalence and incidence of polio  
390 and measles have been reduced substantially through vaccination but both diseases persist. The  
391 2001 Foot and Mouth Disease outbreak in the UK and the 2003 SARS pandemic were new  
392 epidemics that were driven extinct without vaccination before they became endemic, but both  
393 exhibited long tails before eradication was achieved. The 2014-16 Ebola outbreak in West  
394 Africa was eliminated (with vaccination at the end of the outbreak [71]), but eradication took  
395 some time with flare ups occurring in different countries [72,73].

396

397 Past experience therefore raises the possibility that SARS-CoV-2 may not be driven to complete  
398 extinction in the foreseeable future, even if a vaccine is developed and vaccination campaigns  
399 can be implemented. As exemplified by the outbreak of Ebola in the Democratic Republic of the  
400 Congo that has only recently been declared over [74], there is an additional challenge of  
401 assessing whether the virus really is extinct rather than persisting in individuals who do not  
402 report disease [72]. There is a distinct possibility that SARS-CoV-2 could become endemic,  
403 either persisting in populations with limited access to healthcare or circulating in seasonal  
404 outbreaks as the virus evolves. Appropriate communication of these scenarios to the public and  
405 policy-makers – particularly the possibility that SARS-CoV-2 may never be eradicated – is of  
406 obvious importance.

407

## 408 **2 HETEROGENEITIES IN TRANSMISSION**

409 *2.1 HOW MUCH RESOLUTION IS NEEDED WHEN MODELLING HUMAN*  
410 *HETEROGENEITIES?*

411 A common challenge faced by modellers working in outbreak situations is the tension between  
412 making models more complex (and possibly therefore seeming more realistic and convincing to  
413 stakeholders) and maintaining simplicity (for scientific parsimony when data are sparse and for  
414 expediency when predictions are required at very short notice by policy-makers) [75]. How to  
415 strike the correct balance is not a settled question, especially given the growing amount of  
416 available data on human demography and behaviour. Indeed, outputs of multiple models with  
417 different levels of complexity can provide useful and complementary information. Many sources  
418 of heterogeneity between individuals (and between populations) exist, including the strong skew  
419 of severe COVID-19 outcomes towards the elderly and individuals from specific groups. Here,  
420 we focus on two sources of heterogeneity in human populations that must be considered when  
421 modelling exit strategies: spatial contact structure and health vulnerabilities.

422

423 There has been considerable success in modelling local contact structure, both in terms of spatial  
424 heterogeneity (distinguishing local and long-distance contacts) and in local mixing structures  
425 such as households and workplaces. However, challenges include tracking pathogen transmission  
426 and assessing changes when contact networks are altered. In spatial models with only a small  
427 number of near-neighbour contacts, the number of new infections grows slowly, so that  
428 each generation of infected individuals is only slightly larger than the previous one. As a result,  
429 in those models,  $R(t)$  cannot significantly exceed its threshold value of one [76]. In contrast,  
430 models accounting for transmission within closely interacting groups explicitly contain a  
431 mechanism that has a multiplier effect on the value of  $R(t)$  [66]. Another challenge is in  
432 modelling the spatiotemporal structure of human populations: the spatial distribution of

433 individuals is important, but long-distance contacts make populations more connected than  
434 depicted by simple percolation-type spatial models [76]. Clustering and pair approximation  
435 models can capture some aspects of spatial heterogeneities [77], which can result in exponential  
436 rather than linear growth in case numbers [78].

437

438 While modelling frameworks exist to include almost any kind of spatial stratification, ensuring  
439 that model outputs are meaningful for exit strategy planning relies on appropriate calibration  
440 with data. This brings in challenges of merging multiple data types with different stratification  
441 levels. For example, case notification data may be aggregated at a broad regional level within a  
442 country, while mobility data from past surveys might be available at finer scales within regions.  
443 Another challenge is to determine the appropriate scale at which to introduce or lift  
444 interventions. Although government policies are usually directed at whole populations within  
445 relevant administrative units (country-wide or smaller), more effective interventions and exit  
446 strategies may exist that target specific parts of the population [79]. Here, modelling can be  
447 helpful to account for operational costs and imperfect implementation that will offset expected  
448 epidemiological gains.

449

450 The structure of host vulnerability to disease is generally reported via risk factors: many factors  
451 have been considered, including age, sex and ethnicity [80,81]. From a modelling perspective, a  
452 number of open questions exist. To what extent does heterogeneous vulnerability at an individual  
453 level affect the impact of exit strategies beyond the reporting of potential outcomes, if at all?  
454 Where host vulnerability is an issue, is it necessary to account for considerations other than  
455 reported risk factors, as these may be proxies for underlying causes? Another important aspect is

456 that, once communicated to the public, the results of modelling could create behavioural  
457 feedback that might help or hinder exit strategies; some sensitivity analyses would be useful. As  
458 with the questions around spatial heterogeneity, modelling variations in host vulnerability could  
459 improve proposed exit strategies, and modelling might be used to explore how these are targeted  
460 and communicated [5]. Finally, heterogeneities in space and vulnerabilities may interact;  
461 modelling these may reveal surprises that can be explored further.

462

## 463 2.2 *WHAT ARE THE ROLES OF NETWORKS AND HOUSEHOLDS IN SARS-* 464 *COV-2 TRANSMISSION?*

465 In combination with contact tracing, NPIs reduce the opportunity for transmission by breaking  
466 up contact networks (closing workplaces, schools, preventing large gatherings), reducing the  
467 chance of transmission where links cannot be broken (e.g. wearing masks, sneeze barriers) and  
468 identifying infected individuals (temperature checks [82], diagnostic testing [83]). Network  
469 models [84,85] aim to split pathogen transmission into opportunity (number of contacts) and  
470 transmission probability, using social network data that can be measured directly (through  
471 devices such as mobility tracking and contact diaries) and indirectly (through traffic flow and co-  
472 occurrence studies). This brings new issues: for example, are observed networks missing key  
473 routes of transmission, such as indirect contact via contaminated surfaces, or adding noise in the  
474 form of contacts that are low risk [86]? How we measure and interpret contact networks depends  
475 on the geographical and social scale of interest (e.g. wider community spread or closed  
476 populations such as prisons and care homes; or sub-populations such as workplaces and schools)  
477 and the timescale over which we want to use the network to understand or predict infection  
478 chains.

479

480 In reality, individuals belong to households, children attend schools and adults mix in  
481 workplaces as well as in social contexts. This has led to the development of household models  
482 [66,87–90], multilayer networks [91], bipartite networks [92,93] and networks that are  
483 geographically- and socially-embedded to reflect location and travel habits [94]. These  
484 modelling tools can play a key role in understanding and monitoring transmission, and exploring  
485 what-if scenarios, at the point of exiting a lockdown: in particular, they can inform whether or  
486 not, and how quickly, households or local networks merge to form larger and possibly denser  
487 contact networks in which local outbreaks can emerge. Variations between regions and socio-  
488 economic factors can also be explored.

489

490 Contact tracing, followed by isolation or treatment of infected contacts, is a well-established  
491 method of disease control. The structure of the contact network is important in determining  
492 whether or not contact tracing will be successful. For example, contact tracing in clustered  
493 networks is known to be more effective than in equivalent non-clustered networks [95,96], since  
494 a potentially infected contact can be traced from multiple different sources. Knowledge of the  
495 contact network enhances understanding of the correlation structure that emerges as a result of  
496 the epidemic. The first wave of an epidemic will typically infect many of the highly connected  
497 nodes and will move slowly to less connected parts of the network leaving behind islands of  
498 removed and susceptible individuals. This can lead to a correlated structure of susceptible and  
499 recovered nodes that may make the networks less vulnerable to later epidemic waves [97], and  
500 has implications for herd immunity (Section 1.2).

501

502 In heterogeneous populations, relatively few very well-connected people can have a large impact  
503 on the spread of a pathogen and be major hubs for transmission. Such individuals are often  
504 referred to as super-spreaders [98,99] and some theoretical approaches to controlling epidemics  
505 are based on targeting them [100]. However, particularly for respiratory diseases, whether  
506 specific individuals can be classified as potential super-spreaders, or instead whether any  
507 infected individual has the potential to generate super-spreading events, is debated [37,101,102].

508

509 As control policies are gradually lifted, the disrupted contact network will start to form again.  
510 Understanding how proxies for social networks (which can be measured in near-real time using  
511 mobility data, electronic sensors or trackers) relate to transmission requires careful consideration.  
512 Using observed contacts to predict virus spread might be successful if these quantities are  
513 heavily correlated, but one aim of NPIs should be at least a partial decoupling of the two, so that  
514 society can reopen but transmission remains controlled. The extent to which this is possible is  
515 unclear and is likely to vary between regions. Currently, a key empirical and theoretical  
516 challenge is to understand how households are connected and how this is affected by school  
517 opening (Section 2.3). An important area for further research is to improve our understanding of  
518 the role of within-household transmission in the ongoing COVID-19 pandemic. In particular, do  
519 sustained infection chains within households lead to amplification of infection rates between  
520 households despite lockdowns aimed at minimising between-household transmission?

521

522 Even for relatively well-studied household models, theoretical development of methods  
523 accommodating time-varying parameters such as variable adherence to household-based policies  
524 and/or compensatory behaviour would be valuable to inform future control policies. It would be

525 useful to compare interventions and de-escalation procedures in different countries to gain  
526 insight into: how contact and transmission networks vary between regions; the role of different  
527 household structures in the spread and severity of outcomes (accounting for different household  
528 sizes and age-structures); the cost-effectiveness of different policies, such as household-based  
529 isolation and quarantine in the UK compared to out-of-household quarantine in Australia and  
530 Hong Kong. First Few X (FFX) studies [103,104], now adopted in several countries, provide the  
531 opportunity not only to improve our understanding of critical epidemiological characteristics  
532 (such as incubation periods, generation intervals and the roles of asymptomatic and  
533 presymptomatic transmission) but also to make many of the comparisons just outlined.

534

### 535 *2.3 WHAT IS THE ROLE OF CHILDREN IN SARS-COV-2 TRANSMISSION?*

536 An early intervention implemented in many countries was school closure, which is frequently  
537 used during influenza pandemics [105,106]. Further, playgrounds were closed and strict social  
538 distancing has kept children separated. However, the role of children in SARS-CoV-2  
539 transmission is unclear. Early signs from Wuhan (China), echoed elsewhere, showed many fewer  
540 cases in under 20s than might have been expected. There are three aspects of the role of children  
541 in transmission: i) susceptibility to infection; ii) infectiousness once infected; iii) propensity to  
542 develop disease if infected [107–109]. Evidence for variation in age-specific susceptibility to  
543 infection and infectiousness is mixed, with infectiousness the more difficult to quantify.  
544 However, evidence is emerging of lower susceptibility to infection in children compared to  
545 adults [110], although the mechanism underlying this is unknown and it may not be generalisable  
546 to all settings. Once infected, children appear to have a milder course of infection than adults,

547 and it has been suggested that children have a higher probability of a fully subclinical course of  
548 infection.

549

550 Reopening schools is of clear importance both in ensuring equal access to education and  
551 enabling caregivers to return to work. However, the risk of transmission within schools and the  
552 potential impact on the rate of community transmission needs to be understood so that policy-  
553 makers can balance the potential benefits and harms. As schools begin to reopen there are key  
554 questions that models can help with, and major knowledge gaps that prevent clear answers. The  
555 most pressing question at a regional and national level is the extent to which school restarting  
556 will affect population-level transmission, characterised by  $R(t)$  (Section 1.1). Clearer  
557 quantification of the role of children could have come from analysing the effects of school  
558 closures in different countries in February and March, but as described in the Introduction,  
559 closures generally coincided with many other interventions and so it has proved difficult to  
560 unpick the effects of individual measures [7]. Almost all schools in Sweden stayed open to  
561 under-16s (with the exception of one school that closed for two weeks [111]), and schools in  
562 some other countries are beginning to reopen with social distancing measures in place, providing  
563 a potential opportunity to improve our understanding of within-school transmission. Models can  
564 also inform the design of studies to generate the data required to answer key questions.

565

566 The effect of opening schools on  $R(t)$  also depends on other changes in the rest of the  
567 community. Children, teachers, and support staff are members of households, and lifting  
568 restrictions may therefore affect all members. Modelling school reopening must account for all  
569 changes in contacts of household members [112], noting that the impact on  $R(t)$  may depend on

570 the other interventions in place at that time. The relative risk of restarting different school years  
571 (or even universities) does not affect the population  $R(t)$  straightforwardly, since older children  
572 tend to live with adults who are older (compared to younger children), and households with older  
573 individuals are at greater risk of seeing severe outcomes compared to households with younger  
574 ones. Thus, decisions about which age groups return to school first and how they are grouped at  
575 school must balance the risks of transmission between children at school, transmission to and  
576 between their teachers, and transmission to and within the households of those children.

577

578 Return to school affects the number of physical contacts that teachers and support staff have.  
579 Schools will not be the same environments as prior to lockdown, since physical distancing  
580 measures will be in place. These include smaller classes and changes in layout, plus increased  
581 hygiene measures to decrease transmission. This is critical to reduce SARS-CoV-2 spread  
582 between teachers as well as from teachers to children (and, perhaps to a lesser extent, from  
583 children to teachers). Some teachers may be unlikely to return to school because of the presence  
584 of underlying conditions and a need to “shield”, and if there is transmission within schools, there  
585 may be absenteeism following infection. Models must therefore consider the different effects on  
586 transmission of pre- and post-lockdown school environments. Post-lockdown, with strong social  
587 distancing in place in the wider community, reopening schools could link subcommunities of the  
588 population together, and models can be used to estimate the wider effects on population  
589 transmission as well as those within schools themselves. These estimates are likely to play a  
590 central role in decisions surrounding when and how to reopen schools in different countries.

591

592 *2.4 THE PANDEMIC IS SOCIAL: HOW CAN WE MODEL THAT?*

593 As the pandemic progresses, so does the need for different modelling approaches that account for  
594 population structure and heterogeneity. While these effects can be approximated in standard  
595 compartmental epidemiological models [2,72,113], such models can become highly complex and  
596 cumbersome to specify and solve as more sources of heterogeneity are introduced. An alternative  
597 modelling paradigm is agent-based modelling. Agent-based models (ABM) allow complex  
598 systems such as societies to be represented, using virtual agents programmed to have behavioural  
599 and individual characteristics (age, sex, ethnicity, income, employment status, etc.) as well as the  
600 capacity to interact with other agents [114]. In addition, ABM can include the effects of societal-  
601 level factors such as the influence of social media, regulations and laws, and community norms.  
602 In more sophisticated ABM, agents can anticipate and react to scenarios, and learn by trial and  
603 error or by imitation. ABM represent a way to model systems in which there are feedbacks,  
604 tipping points, the emergence of higher-level properties from the actions of individual agents,  
605 adaptation, and multiple scales of organisation – all features of the COVID-19 pandemic and  
606 societal reactions to it.

607

608 While ABM arise from a different tradition, they can incorporate the insights of compartmental  
609 models; for example, agents must transition through disease states (or compartments) such that  
610 the mean transition rates correspond to the rates that quantify flows in compartmental models.  
611 However, building an ABM that represents a population on a national scale is a huge challenge  
612 and one that is unlikely be accomplished in a timescale useful for the current pandemic. ABM  
613 often include many parameters, leading to challenges of model parameterisation and a  
614 requirement for careful uncertainty quantification and sensitivity analyses to different inputs. On

615 the other hand, useful ABM do not have to be all-encompassing. There are already several  
616 models accessible to the public that illustrate the effects of policies such as social distancing on  
617 small simulated populations. These models can be very helpful as “thought experiments” to  
618 identify the potential effects of candidate policies such as school re-opening, the consequences of  
619 non-compliance with government edicts and the impacts of restrictions on long-distance travel,  
620 amongst others.

621

622 There are two areas where action should be taken, both of which are long-term and intended to  
623 assist in dealing with the almost inevitable next pandemic rather than this one. First, more data  
624 about people’s ordinary behaviour are required: what individuals do each day (through time-use  
625 diaries), whom they meet (possibly through mobile phone data, assuming consent can be  
626 obtained), and how they understand and act on government regulation, social media influences  
627 and broadcast information [115]. Second, a large, modular ABM should be built that represents  
628 heterogeneities in populations and that is properly calibrated as a social “digital twin” of our own  
629 society, with which we can carry out virtual policy experiments. Had these developments  
630 occurred before, they would have been useful in the current situation. As a result, if these are  
631 done now, they will aid the planning of exit strategies in future.

### 632 **3 DATA NEEDS AND COMMUNICATING UNCERTAINTY**

#### 633 *3.1 WHAT ARE THE ADDITIONAL CHALLENGES OF DATA LIMITED* 634 *SETTINGS?*

635 In most countries, criteria for ending COVID-19 lockdowns rely on tracking trends in numbers  
636 of confirmed cases and deaths, and assessments of transmissibility (Section 1.1). In this section,

637 we focus specifically on issues in determining when interventions should be relaxed in LMICs,  
638 although we note that many of these issues apply everywhere. Perhaps surprisingly, many  
639 concerns relating to data availability and reliability (e.g. lack of clarity about sampling frames)  
640 remain in countries worldwide. Other difficulties have also been experienced in many countries  
641 throughout the pandemic (e.g. shortages of vital supplies, perhaps due in developed countries to  
642 previous emphasis on healthcare system efficiency rather than pandemic preparedness [116]).

643

644 In many countries, data about the COVID-19 pandemic and about the general population and  
645 context can be unreliable or lacking. Because of limited healthcare access and utilisation, there  
646 can be fewer opportunities for diagnosis and subsequent confirmation of cases in LMICs  
647 compared to other settings, unless there are active programmes [117]. Distrust can make  
648 monitoring programmes difficult, and complicate control activities like test-trace-isolate  
649 campaigns [118,119]. Other options for monitoring – such as assessing excess disease from  
650 general reporting of acute respiratory infections or influenza-like-illness – require historical  
651 baselines that may not exist [120,121]. In general, while many LMICs will have a well-served  
652 fraction of the population, dense peri-urban and informal settlements are typically outside that  
653 population and may rapidly become a primary concern for transmission [122]. Since confirmed  
654 case numbers in these populations are unlikely to provide an accurate representation of the  
655 underlying epidemic, reliance on alternative measures such as clinically diagnosed cases may be  
656 necessary to understand the epidemic trajectory. Some tools for rapid assessment of mortality in  
657 countries where the numbers of COVID-19 related deaths are hard to track are starting to  
658 become available [123].

659

660 In addition to the challenges in understanding the pandemic in these settings, metrics on health  
661 system capacity (including resources such as beds and ventilators), as needed to set targets for  
662 control, are often poorly documented [124]. Furthermore, the economic hardships and competing  
663 health priorities in low-resource settings change the objectives of lifting restrictions – for  
664 example, hunger due to loss of jobs and changes in access to routine health care (e.g. HIV  
665 services and childhood vaccinations) as a result of lockdown have the potential to cost many  
666 lives in themselves, both in the short- and long-term [125,126], and this must be accounted for  
667 when deciding how to relax COVID-19 public health measures. To assess the costs and benefits  
668 of lifting restrictions appropriately, additional data on these conditions may be required. In many  
669 settings, these data are currently unavailable.

670

671 These challenges suggest three key elements of modelling efforts for moving forward in data-  
672 limited settings: i) identification of policy responses that are robust to missing information; ii)  
673 value-of-information analyses to prioritise additional data collection and curation efforts; iii)  
674 development of methods that use metadata to interpret epidemiological patterns.

675

676 In settings where additional data collection is not affordable, models may provide a clearer  
677 picture by incorporating available metadata, such as testing and reporting rates through time,  
678 sample backlogs, and suspected COVID-19 cases based on syndromic surveillance. By  
679 identifying the most informative data, modelling could encourage countries to share available  
680 data more widely. For example, in high incidence settings, burial reports and death certificates  
681 may be available, and these data can provide information on the demographics that influence the

682 infection fatality rate. These can in turn reveal potential COVID-19 deaths classified as other  
683 causes and hence missing from COVID-19 attributed death notifications.

684

685 In general, supporting LMICs calls for creativity in the data that might be incorporated in models  
686 and in the response activities that are undertaken. Some LMICs have managed the COVID-19  
687 pandemic successfully so far (e.g. Vietnam, as well as Trinidad and Tobago [127]). However,  
688 additional support in LMICs is required: data limited settings represent uniquely high stakes.

689

### 690 *3.2 WHICH DATA SHOULD BE COLLECTED AS COUNTRIES EMERGE* 691 *FROM LOCKDOWN, AND WHY?*

692 Identifying the effects of the different components of lockdown is important to understand how –  
693 and in which order – interventions should be released. The impact of previous measures must be  
694 understood both to inform policy in real-time and to ensure that lessons can be learnt from the  
695 current pandemic.

696

697 Models vary from those that include few parameters but can offer powerful and robust insights  
698 into the potential impacts of different strategies, to highly complex simulations aiming to capture  
699 all nuances affecting transmission. Complex simulations are often sensitive to uncertainties in  
700 the many assumed parameters and model structure. Ultimately, all models require information to  
701 make their predictions relevant to the ongoing pandemic. Data from PCR tests for presence of  
702 active virus and serological tests for antibodies, together with data on COVID-19 related deaths,  
703 are freely available via a number of internet sites (e.g. [128]). However, metadata associated with  
704 testing protocols (e.g. reason for testing, type of test, breakdowns by age and underlying health

705 conditions) and the definition of COVID-19 related death, which are needed to quantify sources  
706 of potential bias and parameterise models correctly, are often unavailable. Data from individuals  
707 likely to have been exposed to the virus (e.g. within households of known infected individuals),  
708 but who may or may not have contracted it themselves, are also useful for model  
709 parameterisation [129]. New sources of data exist, ranging from tracking data from mobile  
710 phones [130] to social media surveys [131] and details of interactions with public health  
711 providers [132]. Although potentially valuable, these data sources bring with them biases that are  
712 not always understood perfectly. These types of data are also often subject to data protection  
713 and/or costly fees, meaning that they are not readily available to many modelling groups. Mixing  
714 patterns by age were reasonably well-characterised before the current pandemic [133,134]  
715 (particularly for adults of different ages) and have been used extensively in existing models.  
716 However, there are gaps in these data and uncertainty in the impacts that different interventions  
717 have had on mixing. Predictive models for policy tend to make broad assumptions about the  
718 effects of elements of social distancing [135], although results of studies that attempt to estimate  
719 effects in a more data-driven way are beginning to emerge [136]. The future success of  
720 modelling efforts to understand when controls should be relaxed or tightened depends critically  
721 on whether, and how accurately as well as how quickly, the effects of different elements of  
722 lockdown can be parameterised.

723

724 Given the many differences in lockdown implementation between countries, cross-country  
725 comparisons offer an opportunity to estimate the effects on transmission of each component of  
726 lockdown [7]. However, there are many challenges in comparing SARS-CoV-2 dynamics in  
727 different countries. Alongside variability in the timing, type and impact of interventions, the

728 numbers of importations from elsewhere will vary between countries [69,137]. Underlying  
729 differences in mixing, behavioural changes in response to the pandemic, household structures,  
730 occupations and distributions of ages and co-morbidities are likely to be important but uncertain  
731 drivers of transmission patterns. A current research target is to understand the role of weather  
732 and climate in SARS-CoV-2 transmission and severity [138]. Many analyses across and within  
733 countries highlight potential correlations between environmental variables and transmission  
734 [139–144], although sometimes by applying ecological niche modelling frameworks that are  
735 perhaps ill-suited for modelling a rapidly spreading pathogen [145–147]. Assessments of the  
736 interactions between weather and viral transmissibility are facilitated by the availability of  
737 extensive datasets describing weather patterns, such as the European Centre for Medium-Range  
738 Weather Forecasts ERA5 dataset [148] and simulations of the Community Earth System Model  
739 that can be used to estimate the past, present and future values of meteorological variables  
740 worldwide [149]. It is likely that temperature, humidity and precipitation affect the survival of  
741 SARS-CoV-2 outside the body, and prevailing weather conditions could, in theory, tip  $R(t)$   
742 above or below one. However, the effects of these factors on transmission have not been  
743 established conclusively, and the impact of seasonality on short- or long-term SARS-CoV-2  
744 dynamics is likely to depend on other factors including the timing and impact of interventions,  
745 and the dynamics of immunity [46,150]. At present, it is hard to separate the effects of the  
746 weather on virus survival from other factors including behavioural changes in different seasons  
747 [151]. The challenge of disentangling the impact of variations in weather on transmission from  
748 other epidemiological drivers in different locations is therefore a complex open problem.

749

750 In seeking to understand and compare COVID-19 data from different countries, there is a need to  
751 coordinate the design of epidemiological studies, involving longitudinal data collection and case-  
752 control studies. This will help enable models to track the progress of the epidemic and the  
753 impacts of control policies internationally. It will also allow more refined conclusions than those  
754 that follow from population data alone. Countries with substantial epidemiological modelling  
755 expertise should support epidemiologists elsewhere with standardised protocols for collecting  
756 data and using models to inform policy. There is also a need to share models to be used “in the  
757 field” in different settings. Collectively, these efforts will ensure that models are parameterised  
758 as realistically as possible for the particular settings in which they are to be used. In turn, as  
759 interventions are relaxed, this will allow us to detect the earliest possible reliable signatures of a  
760 resurgence in cases should it occur, leading to an unambiguous characterisation of when it is  
761 necessary for some interventions to be reintroduced.

762

### 763 *3.3 HOW SHOULD MODEL AND PARAMETER UNCERTAINTY BE* 764 *COMMUNICATED?*

765 SARS-CoV-2 transmission models have played a crucial role in shaping policies in different  
766 countries, and their predictions (and the scenarios that they have been used to explore) have been  
767 a regular feature of media coverage of the pandemic [135,152]. Understandably, both policy-  
768 makers and journalists generally prefer single “best guess” figures from models, rather than a  
769 range of plausible values. However, the ranges of outputs that modellers provide include  
770 important information about the variety of possible scenarios and guard against over-  
771 interpretation of model results. Not presenting information about uncertainty can convey a false

772 confidence in predictions, and it is critical that modellers present uncertainty in a way that is  
773 understandable and useful for policy-makers and the public [75].

774

775 There are numerous and often inextricable ways in which uncertainty enters the modelling  
776 process. Any model includes assumptions that inevitably vary according to judgements regarding  
777 which features should be included in the model [1,94] and which datasets are used to inform the  
778 model [153]. Within any model, ranges of parameter values can be considered to allow for  
779 uncertainty about clinical characteristics of COVID-19 (e.g. the infectious period and case  
780 fatality rate) [154]. Alternative initial conditions (e.g. numbers and locations of imported cases  
781 seeding national outbreaks, or levels of population susceptibility) can be considered. In  
782 modelling exit strategies, when surges in cases starting from small numbers may occur and  
783 where predictions will depend on characterising epidemiological parameters as accurately as  
784 possible, stochastic models may be of particular importance. Not all the uncertainty arising from  
785 such stochasticity will be reduced by collecting more data; it is inherent to the process.

786

787 Where models have been developed for similar purposes, formal methods of comparison can be  
788 applied, but in epidemiological modelling, models often have been developed to address  
789 different questions, possibly involving “what-if?” scenarios, in which case only qualitative  
790 comparisons can be made. The ideal outcome for policy-making is when different models  
791 generate similar conclusions, demonstrating robustness to the detailed assumptions  
792 involved. Where there is a narrowly defined requirement, such as short-term predictions of cases  
793 and deaths, more tractable tools for comparing the outputs from different models in real-time  
794 would be valuable. One possible approach is to assess and compare the models’ past

795 performance at making predictions [33,155]. The use of ensemble estimates, most commonly  
796 applied for forecasting disease trajectories, is a way to synthesise multiple models' predictions  
797 into a single estimate [156,157]. The assessment and comparison of past performance can then  
798 be used to weight models in the ensemble. Such approaches typically lead to improved point and  
799 variance estimates.

800

801 To deal with parameter uncertainty, a common approach is to perform sensitivity analyses in  
802 which model parameters are repeatedly sampled from a range of plausible values, and the  
803 resulting model predictions compared; both classical and Bayesian statistical approaches can be  
804 employed [158–160]. Methods of uncertainty quantification provide a framework in which  
805 uncertainties with regard to model structure, values of epidemiological parameters, and data can  
806 be considered together. In practice, there is usually only a limited number of possible policies  
807 that can be implemented. An important question is often whether or not the optimal policy can be  
808 identified given the uncertainties we have described, and decision analyses can be helpful for this  
809 purpose [161,162].

810

811 In summary, communication of uncertainty to policy-makers and the general public remains a  
812 challenging area. Different levels of detail may be required for different audiences. There are  
813 many subtleties: for instance, almost any epidemic model can provide an acceptable fit to data in  
814 the early phase of an outbreak, since models almost invariably predict exponential growth. This  
815 can induce an artificial belief that the model must be based on sensible underlying assumptions,  
816 and the true uncertainty about such assumptions has vanished. Clear presentation of data is  
817 critical. For example, it is important not simply to present data on the numbers of cases, but also

818 include information about the numbers of individuals who have been tested. In addition, clear  
819 statements of the individual values used to calculate quantities such as the case fatality rate are  
820 vital, so that studies can be interpreted and compared correctly [163,164]. Going forwards,  
821 improved communication of model and parameter uncertainty is essential as models are used to  
822 predict the effects of different exit strategies.

## 823 **SUMMARY AND DISCUSSION**

824 In this article, we have highlighted a number of ongoing challenges in modelling the COVID-19  
825 pandemic, and uncertainties faced by most countries devising lockdown exit strategies. It is  
826 important, however, to put these issues into context: at the start of 2020 the virus was unknown,  
827 and its pandemic potential only became apparent at the end of January. The speed with which the  
828 scientific and public health communities came together to tackle this challenge and the openness  
829 in sharing data, methods and analyses are unprecedented. At very short notice, epidemic  
830 modellers were able to mobilise a substantial workforce – mostly on a voluntary basis – and  
831 state-of-the-art computational models. Far from the rough-and-ready tools sometimes depicted in  
832 the media, the modelling effort deployed since January is a collective and multi-pronged effort  
833 benefitting from years of experience of outbreak modelling, often combined with long-term  
834 engagement with public health agencies and policy-makers.

835

836 Drawing on this collective expertise, the virtual meeting convened in mid-May by the Isaac  
837 Newton Institute generated a clear overview of the steps needed to improve and validate the  
838 scientific advice to guide lockdown exit strategies. Importantly, the roadmap outlined in this  
839 paper is meant to be feasible within the lifetime of the pandemic. Unlike some scientific fields,  
840 infectious disease epidemiology does not have the luxury of waiting for all data to become

841 available before fully validated models must be developed. As discussed here, the solution lies in  
842 using diverse and flexible modelling frameworks that can be revised and improved iteratively as  
843 more data become available. Equally important is the ability to assess the data critically and  
844 bring together evidence from multiple fields: numbers of cases and deaths reported by regional  
845 or national authorities only represent a single source of data, and expert knowledge is even  
846 required to interpret these data correctly.

847

848 In this spirit, our first recommendation is to improve estimates of key epidemiological  
849 parameters. This requires close collaboration between epidemic modellers and the individuals  
850 and organisations that collect epidemic data, so that the caveats and assumptions on each side are  
851 clearly presented and understood. That is a key message from the first section of this study, in  
852 which the relevance of theoretical concepts and model parameters in the real world was  
853 demonstrated: far from ignoring the complexity of the pandemic, models draw from different  
854 sources of expertise to make sense of imperfect observations. By acknowledging the simplifying  
855 assumptions of models, we can assess their relative impacts and validate or replace them as new  
856 evidence becomes available.

857

858 Our second recommendation is to seek to understand important sources of heterogeneity that  
859 appear to be driving the pandemic and its response to interventions. Agent-based modelling  
860 represents one possible framework for modelling complex dynamics, but standard epidemic  
861 models can also be extended to include age groups or any other relevant strata in the population  
862 as well as spatial structure. Network models provide computationally efficient approaches to

863 capture different types of epidemiological and social interactions. Importantly, many modelling  
864 frameworks provide avenues for collaboration with other fields, such as the social sciences.

865

866 Our third and final recommendation regards the need to focus on data requirements, particularly  
867 (although not exclusively) in resource limited settings such as LMICs. Understanding the data  
868 required for accurate predictions in different countries requires close communication between  
869 modellers and governments, public health authorities and the general public. While this  
870 pandemic casts a light on social inequalities between and within countries, modellers have a  
871 crucial role to play in sharing knowledge and expertise with those who need it most. In LMICs,  
872 cost-effective guidance can be provided by models validated with global data. During the  
873 pandemic so far, countries that might be considered similar in many respects have often differed  
874 in their policies; either in the choice or the timing of restrictions imposed on their respective  
875 populations. Models are important for drawing reliable inferences from global comparisons of  
876 the relative impacts of different control measures. All too often, national death tolls have been  
877 used for political purposes in the media, attributing the apparent success or failure of particular  
878 countries to specific policies without presenting any convincing evidence. Modellers must work  
879 closely with policy-makers, journalists and social scientists to improve the communication of  
880 rapidly changing scientific knowledge while conveying the multiple sources of uncertainty in a  
881 meaningful way.

882

883 We are now moving into a stage of the COVID-19 pandemic in which data collection and novel  
884 research to inform the modelling issues discussed here are both possible and essential for global  
885 health. These are international challenges that require an international collaborative response

886 from diverse scientific communities, which we hope that this article will stimulate. This is of  
887 critical importance, not only to tackle this pandemic but also to improve the response to future  
888 outbreaks of emerging infectious diseases.

## 889 **References**

- 890 1. Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, et al. The effect of control  
891 strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a  
892 modelling study. *Lancet Public Heal.* 2020;5: e261–e270.
- 893 2. Thompson RN. Epidemiological models are important tools for guiding COVID-19 interventions.  
894 *BMC Med.* 2020;18: 152.
- 895 3. Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and severity in China  
896 outside Hubei after control measures, and second-wave scenario planning: a modelling impact  
897 assessment. *Lancet.* 2020;395: 1382–1393.
- 898 4. Rawson T, Brewer T, Veltcheva D, Huntingford C, Bonsall MB. How and when to end the COVID-  
899 19 lockdown: an optimisation approach. *Front Public Heal.* 2020;8: 262.
- 900 5. van Bunnik BAD, Morgan ALX, Bessell P, Calder-Gerver G, Zhang F, Haynes S, et al.  
901 Segmentation and shielding of the most vulnerable members of the population as elements of an  
902 exit strategy from COVID-19 lockdown. *medRxiv.* 2020.
- 903 6. White LF, Moser CB, Thompson RN, Pagano M. Statistical estimation of the reproductive number  
904 from case notification data: a review. *Am J Epidemiol.* 2020.
- 905 7. Flaxman S, Mishra S, Gandy A, Unwin HJT, Coupland H, Mellan TA, et al. Report 13: Estimating  
906 the number of infections and the impact of non-pharmaceutical interventions on COVID-19 in 11  
907 European countries. 2020. Available: [www.imperial.ac.uk/media/imperial-college/medicine/mrc-  
908 gida/2020-03-30-COVID19-Report-13.pdf](http://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-03-30-COVID19-Report-13.pdf)
- 909 8. Abbott S, Hellewell J, Thompson RN, Sherratt K, Gibbs HP, Bosse NI, et al. Estimating the time-  
910 varying reproduction number of SARS-CoV-2 using national and subnational case counts.  
911 *Wellcome Open Res.* 2020;5: 112.

- 912 9. Cowling BJ, Ali ST, Ng TW, Tsang TK, Li JC, Fong MW, et al. Impact assessment of non-  
913 pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an  
914 observational study. *Lancet Public Heal.* 2020;5: e279–e288.
- 915 10. Gostic KM, McGough L, Baskerville E, Abbott S, Joshi K, Tedijanto C, et al. Practical  
916 considerations for measuring the effective reproductive number,  $R_t$ . medRxiv. 2020.
- 917 11. Haydon DT, Chase-Topping M, Shaw DJ, Matthews L, Friar JK, Wilesmith J, et al. The  
918 construction and analysis of epidemic trees with reference to the 2001 UK foot-and-mouth  
919 outbreak. *Proc R Soc B Biol Sci.* 2003;270: 121–127.
- 920 12. Birrell P, Blake J, van Leeuwen E, De Angelis D, Joint PHE Modelling Cell, MRC Biostatistics Unit  
921 COVID-19 Working Group. Nowcasting and Forecasting Report. 2020 [cited 21 May 2020].  
922 Available: <https://www.mrc-bsu.cam.ac.uk/now-casting/>
- 923 13. Government Office for Science. Government publishes latest R number. 2020. Available:  
924 <https://www.gov.uk/government/news/government-publishes-latest-r-number>
- 925 14. UK Government Cabinet Office. Our plan to rebuild: The UK government’s COVID-19 recovery  
926 strategy. 2020.
- 927 15. Cauchemez S, Boëlle P, Thomas G, Valleron AJ. Estimating in real time the efficacy of measures  
928 to control emerging communicable diseases. 2006. 164: 591–597.
- 929 16. Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory syndrome reveal  
930 similar impacts of control measures. *Am J Epidemiol.* 2004;160: 509–516.
- 931 17. Cori A, Ferguson NM, Fraser C, Cauchemez S. A new framework and software to estimate time-  
932 varying reproduction numbers during epidemics. *Am J Epidemiol.* 2013;178: 1505–12.
- 933 18. Thompson RN, Stockwin JE, Gaalen RD Van, Polonsky JA, Kamvar ZN, Demarsh PA, et al.  
934 Improved inference of time-varying reproduction numbers during infectious disease outbreaks.  
935 *Epidemics.* 2019;19: 100356.
- 936 19. Lemaitre JC, Perez-Saez J, Azman AS, Rinaldo A, Fellay J. Assessing the impact of non-  
937 pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland. *Swiss Med Wkly.*  
938 2020;150: w20295.
- 939 20. Nishiura H, Chowell G. The effective reproduction number as a prelude to statistical estimation of

- 940 time-dependent epidemic trends. *Mathematical and Statistical Estimation Approaches in*  
941 *Epidemiology*. 2009. pp. 103–121.
- 942 21. Stadler R, Kuhnert D, Bonhoeffer S, Drummond AJ. Birth–death skyline plot reveals temporal  
943 changes of epidemic spread in HIV and hepatitis C virus (HCV). *PNAS*. 2013;110: 228–233.
- 944 22. Volz EM, Didelot X. Modeling the growth and decline of pathogen effective population size  
945 provides insight into epidemic dynamics and drivers of antimicrobial resistance. *Syst Biol*. 2018;67:  
946 719–728.
- 947 23. Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH. The epidemic behavior  
948 of the hepatitis C virus. *Science* (80- ). 2001;22: 2323–2325.
- 949 24. Parag K V, Donnelly CA. Adaptive estimation for epidemic renewal and phylogenetic skyline  
950 models. *Syst Biol*. 2020;1: syaa035.
- 951 25. Donker T, van Boven M, van Ballegooijen WM, van't Klooster TM, Wielders CC, Wallinga J.  
952 Nowcasting pandemic influenza A/H1N1 2009 hospitalizations in the Netherlands. *Eur J*  
953 *Epidemiol*. 2011;26: 195–201.
- 954 26. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the effects  
955 of non-pharmaceutical interventions on COVID-19 in Europe. *Nature*. 2020.
- 956 27. Richardson WH. Bayesian-based iterative method of image restoration. *J Opt Soc Am*. 1972;62:  
957 55–59.
- 958 28. Lucy LB. An iterative technique for the rectification of observed distributions. *Astron J*. 1974;79:  
959 745–754.
- 960 29. Goldstein E, Dushoff J, Ma J, Plotkin JB, Earn DJD, Lipsitch M. Reconstructing influenza  
961 incidence by deconvolution of daily mortality time series. *PNAS*. 2009;106: 21829.
- 962 30. Seaman S, De Angelis D, MRC-BSU COVID-19 Working Group, PHE Modelling Cell. Adjusting  
963 COVID-19 deaths to account for reporting delay. 2020. Available: [https://www.mrc-  
964 bsu.cam.ac.uk/wp-content/uploads/2020/05/Adjusting-COVID-19-deaths-to-account-for-reporting-  
965 delay.pdf](https://www.mrc-<br/>964 bsu.cam.ac.uk/wp-content/uploads/2020/05/Adjusting-COVID-19-deaths-to-account-for-reporting-<br/>965 delay.pdf)
- 966 31. Vollmer MAC, Mishra S, Unwin HJT, Gandy A, Mellan TA, Bradley V, et al. Report 20: Using  
967 mobility to estimate the transmission intensity of COVID-19 in Italy: A subnational analysis with

- 968 future scenarios. 2020. Available: [www.imperial.ac.uk/media/imperial-college/medicine/mrc-](http://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-05-04-COVID19-Report-20.pdf)  
969 [gida/2020-05-04-COVID19-Report-20.pdf](http://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-05-04-COVID19-Report-20.pdf)
- 970 32. Svensson A. A note on generation times in epidemic models. *Math Biosci.* 2007;208: 300–311.
- 971 33. Parag K V, Donnelly C. Using information theory to optimise epidemic models for real-time  
972 prediction and estimation. *PLoS Comput Biol.* 2020;16: e1007990.
- 973 34. Parag K V, Donnelly CA, Jha R, Thompson RN. An exact method for quantifying the reliability of  
974 end-of-epidemic declarations in real time. *medRxiv.* 2020.
- 975 35. Golding N, Shearer FM, Moss R, Dawson P, Gibbs L, Alisic E, et al. Estimating temporal variation  
976 in transmission of COVID-19 and adherence to social distancing measures in Australia. 2020.  
977 Available: [https://www.doherty.edu.au/uploads/content\\_doc/Technical\\_report\\_15\\_Maypdf.pdf](https://www.doherty.edu.au/uploads/content_doc/Technical_report_15_Maypdf.pdf)
- 978 36. Glass K, Mercer GN, Nishiura H, McBryde ES, Becker NG. Estimating reproduction numbers for  
979 adults and children from case data. *J R Soc Interface.* 2011;8: 1248–1259.
- 980 37. Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of individual  
981 variation on disease emergence. *Nature.* 2005;438: 355–359.
- 982 38. Woolhouse MEJ, Dye C, Etard JF, Smith T, Charlwood JD, Garnett GP, et al. Heterogeneities in  
983 the transmission of infectious agents: Implications for the design of control programs. *PNAS.*  
984 1997;94: 338–342.
- 985 39. Endo A, CMMID COVID-19 working group, Abbott S, Kucharski AJ, Funk S. Estimating the  
986 overdispersion in COVID-19 transmission using outbreak sizes outside China. *Wellcome Open*  
987 *Res.* 2020;5: 67.
- 988 40. Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dorner L, et al. Quantifying SARS-  
989 CoV-2 transmission suggests epidemic control with digital contact tracing. *Science (80- ).* 2020;  
990 eabb6936.
- 991 41. Thompson RN, Lovell-Read FA, Obolski U. Time from symptom onset to hospitalisation of  
992 coronavirus disease 2019 (COVID-19) cases: Implications for the proportion of transmissions from  
993 infectors with few symptoms. *J Clin Med.* 2020;9: 1297.
- 994 42. Du Z, Xu X, Wu Y, Wang L, Cowling BJ, Meyers LA. Serial interval of COVID-19 among publicly  
995 reported confirmed cases. *Emerg Infect Dis.* 2020;26: 1341–1343.

- 996 43. Ganyani T, Kremer C, Chen D, Torneri A, Faes C, Wallinga J, et al. Estimating the generation  
997 interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020.  
998 *Eurosurveillance*. 2020;25: 2000257.
- 999 44. Zhao S. Estimating the time interval between transmission generations when negative values  
1000 occur in the serial interval data: using COVID-19 as an example. *Math Biosci Eng*. 2020;17: 3512.
- 1001 45. Pellis L, Scarabel F, Stage HB, Overton CE, Chappell LH, Lythgoe KA, et al. Challenges in control  
1002 of Covid-19: short doubling time and long delay to effect of interventions. *arXiv*. 2020.
- 1003 46. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics  
1004 of SARS-CoV-2 through the postpandemic period. *Science (80- )*. 2020;368: 860–868.
- 1005 47. Britton T, Ball F, Trapman P. A mathematical model reveals the influence of population  
1006 heterogeneity on herd immunity to SARS-CoV-2. *Science (80- )*. 2020.
- 1007 48. Gomes MGM, Aguas R, Corder RM, King JG, Langwig KE, Souto-Maior C, et al. Individual  
1008 variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold.  
1009 *medRxiv*. 2020.
- 1010 49. UK Government Office for National Statistics. Coronavirus (COVID-19) Infection Survey pilot:  
1011 England, 21 May 2020. 2020. Available:  
1012 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseas  
1013 es/bulletins/coronaviruscovid19infectionsurveypilot/england21may2020](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/england21may2020)
- 1014 50. Metcalf CJE, Farrar J, Cutts FT, Basta NE, Graham AL, Lessler J, et al. Use of serological surveys  
1015 to generate key insights into the changing global landscape of infectious disease. *Lancet*.  
1016 2016;388: 728–730.
- 1017 51. Eckerle I, Meyer B. SARS-CoV-2 seroprevalence in COVID-19 hotspots. *Lancet*. 2020.
- 1018 52. Borremans B, Gamble A, Prager KC, Helman SK, McClain AM, Cox C, et al. Quantifying antibody  
1019 kinetics and RNA shedding during early-phase SARS-CoV-2 infection. *medRxiv*. 2020.
- 1020 53. Altmann DM, Douek DC, Boyton RJ. What policy makers need to know about COVID-19  
1021 protective immunity. *Lancet*. 2020;395: 1527–1529.
- 1022 54. Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. *JAMA*. 2020.
- 1023 55. Hens N, Aerts M, Faes C, Shkedy Z, Lejeune O, Van Damme P, et al. Seventy-five years of

- 1024           estimating the force of infection from current status data. *Epidemiol Infect.* 2010;138: 802–812.
- 1025   56.   Winter AK, Martinez ME, Cutts FT, Moss WJ, Ferrari MJ, Mckee A, et al. Benefits and challenges  
1026           in using seroprevalence data to inform models for measles and rubella elimination. *J Infect Dis.*  
1027           2018;218: 355–364.
- 1028   57.   Keiding N. Age-Specific Incidence and Prevalence: A Statistical Perspective. *J R Stat Soc Ser A.*  
1029           1991;154: 371–412.
- 1030   58.   Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al.  
1031           Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based  
1032           seroepidemiological study. *Lancet.* 2020;6736: 31483–31485.
- 1033   59.   Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, et al. Viral kinetics and antibody responses in  
1034           patients with COVID-19. *medRxiv.* 2020.
- 1035   60.   Thompson RN, Gilligan CA, Cunniffe NJ. When does a minor outbreak become a major epidemic?  
1036           Linking the risk from invading pathogens to practical definitions of a major epidemic. *bioRxiv.*  
1037           2019.
- 1038   61.   Andersson H, Britton T. *Stochastic epidemic models and their statistical analysis.* Springer; 2000.
- 1039   62.   Thompson RN. Novel coronavirus outbreak in Wuhan, China, 2020: Intense surveillance is vital for  
1040           preventing sustained transmission in new locations. *J Clin Med.* 2020;9: 498.
- 1041   63.   Craft ME, Beyer HL, Haydon DT. Estimating the probability of a major outbreak from the timing of  
1042           early cases: an indeterminate problem ? *PLoS One.* 2013;8: e57878.
- 1043   64.   Thompson RN, Gilligan CA, Cunniffe NJ. Detecting presymptomatic infection is necessary to  
1044           forecast major epidemics in the earliest stages of infectious disease outbreaks. *PLoS Comput Biol.*  
1045           2016;12: e1004836.
- 1046   65.   Ballard P, Bean N, Ross J. Intervention to maximise the probability of epidemic fade-out. *Math*  
1047           *Biosci.* 2017;293: 1–10.
- 1048   66.   Ball F, Mollison D, Scalia-Tomba G. Epidemics with two levels of mixing. *Ann Appl Probab.*  
1049           1997;7: 46–89.
- 1050   67.   Bailey NTJ. The use of chain-binomials with a variable chance of infection for the analysis of intra-  
1051           household epidemics. *Biometrika.* 1953;40: 279–286.

- 1052 68. Brightwell G, House T, Luczak M. Extinction times in the subcritical stochastic SIS logistic  
1053 epidemic. *J Math Biol.* 2018;77: 455–493.
- 1054 69. Daon Y, Thompson RN, Obolski U. Estimating COVID-19 outbreak risk through air travel. *J Travel*  
1055 *Med.* 2020; taaa093.
- 1056 70. Linka K, Rahman P, Goriely A, Kuhl E. Is it safe to lift COVID-19 travel bans? The Newfoundland  
1057 story. *medRxiv.* 2020.
- 1058 71. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, et al. Efficacy  
1059 and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim  
1060 results from the Guinea ring vaccination cluster-randomised trial. *Lancet.* 2015;386: 857–866.
- 1061 72. Thompson RN, Morgan OW, Jalava K. Rigorous surveillance is necessary for high confidence in  
1062 end-of-outbreak declarations for Ebola and other infectious diseases. *Philos Trans R Soc B.*  
1063 2019;374: 20180431.
- 1064 73. Lee H, Nishiura H. Sexual transmission and the probability of an end of the Ebola virus disease  
1065 epidemic. *J Theor Biol.* 2019;471: 1–12.
- 1066 74. World Health Organization. 10th Ebola outbreak in the Democratic Republic of the Congo declared  
1067 over; vigilance against flare-ups and support for survivors must continue. 2020. Available:  
1068 [https://www.who.int/news-room/detail/25-06-2020-10th-ebola-outbreak-in-the-democratic-republic-](https://www.who.int/news-room/detail/25-06-2020-10th-ebola-outbreak-in-the-democratic-republic-of-the-congo-declared-over-vigilance-against-flare-ups-and-support-for-survivors-must-continue)  
1069 [of-the-congo-declared-over-vigilance-against-flare-ups-and-support-for-survivors-must-continue](https://www.who.int/news-room/detail/25-06-2020-10th-ebola-outbreak-in-the-democratic-republic-of-the-congo-declared-over-vigilance-against-flare-ups-and-support-for-survivors-must-continue)
- 1070 75. Alahmadi A, Belet S, Black A, Cromer D, Flegg JA, House T, et al. Influencing public health policy  
1071 with data-informed mathematical models of infectious diseases: Recent developments and new  
1072 challenges. *Epidemics.* 2020;32: 100393.
- 1073 76. Riley S, Eames K, Isham V, Mollison D, Trapman P. Five challenges for spatial epidemic models.  
1074 *Epidemics.* 2015;10: 68–71.
- 1075 77. Keeling MJ. The effects of local spatial structure on epidemiological invasions. *Proc R Soc B Biol*  
1076 *Sci.* 1999;266: 859–867.
- 1077 78. Mollison D. Pair approximations for spatial structures? *Oberwolfach Rep.* 2004;1: 2625–2627.
- 1078 79. Thompson RN, Cobb RC, Gilligan CA, Cunniffe NJ. Management of invading pathogens should be  
1079 informed by epidemiology rather than administrative boundaries. *Ecol Modell.* 2016;324: 28–32.

- 1080 80. UK Government Office for National Statistics. Coronavirus-related deaths by ethnic group,  
1081 England and Wales: 2 March 2020 to 10 April 2020. 2020. Available:  
1082 [https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/  
1083 coronavirusrelateddeathsbyethnicgroupenglandandwales/2march2020to10april2020](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/coronavirusrelateddeathsbyethnicgroupenglandandwales/2march2020to10april2020)
- 1084 81. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult  
1085 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395: 1054–  
1086 1062.
- 1087 82. Ng OT, Marimuthu K, Chia PY, Koh V, Chiew CJ, de Wang L, et al. SARS-CoV-2 infection among  
1088 travelers returning from Wuhan, China. *N Engl J Med*. 2020;382: 15.
- 1089 83. Thompson RN, Cunniffe NJ. The probability of detection of SARS-CoV-2 in saliva. *Stat Methods  
1090 Med Res*. 2020;29: 1049–1050.
- 1091 84. Kiss IZ, Miller JC, Simon PL. *Mathematics of epidemics on networks: from exact to approximate  
1092 models*. Springer; 2016.
- 1093 85. Pastor-Satorras R, Castellano C, Van Mieghem P, Vespignani A. Epidemic processes in complex  
1094 networks. *Rev Mod Phys*. 2015;87: 925.
- 1095 86. Álvarez LG, Webb CR, Holmes MA. A novel field-based approach to validate the use of network  
1096 models for disease spread between dairy herds. *Epidemiol Infect*. 2011;139: 1863–1874.
- 1097 87. Ball F, Sirl D, Trapman P. Analysis of a stochastic SIR epidemic on a random network  
1098 incorporating household structure. *Math Biosci*. 2010;224: 53–73.
- 1099 88. Ball F, Pellis L, Trapman P. Reproduction numbers for epidemic models with households and  
1100 other social structures II: Comparisons and implications for vaccination. *Math Biosci*. 2016;274:  
1101 108–139.
- 1102 89. Goldstein E, Paur K, Fraser C, Kenah E, Wallinga J, Lipsitch M. Reproductive numbers, epidemic  
1103 spread and control in a community of households. *Math Biosci*. 2009;221: 11–25.
- 1104 90. Pellis L, Ball F, Trapman P. Reproduction numbers for epidemic models with households and  
1105 other social structures. I. Definition and calculation of  $R_0$ . *Math Biosci*. 2012;235: 85–97.
- 1106 91. Aleta A, Martin-Corral D, Piontti AP y, Ajelli M, Litvinova M, Chinazzi M, et al. Modeling the impact  
1107 of social distancing testing contact tracing and household quarantine on second-wave scenarios of

- 1108 the COVID-19 epidemic. medrxiv. 2020.
- 1109 92. Ball FG, Sirl DJ, Trapman P. Epidemics on random intersection graphs. *Ann Appl Probab.*  
1110 2014;24: 1081–1128.
- 1111 93. Britton T, Deijfen M, Lagerås AN, Lindholm M. Epidemics on random graphs with tunable  
1112 clustering. *J Appl Probab.* 2008;45: 743–756.
- 1113 94. Haw D, Pung R, Read J, Riley S. Social networks with strong spatial embedding generate non-  
1114 standard epidemic dynamics driven by higher-order clustering. bioRxiv. 2019.
- 1115 95. Kiss IZ, Green DM, Kao RR. Disease contact tracing in random and clustered networks. *Proc R*  
1116 *Soc B Biol Sci.* 2005;272: 1407–1414.
- 1117 96. Kretzschmar ME, Rozhnova G, Bootsma M, van Boven ME, van de Wijert J, Bonten M. Impact of  
1118 delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. *Lancet*  
1119 *Public Heal.* 2020.
- 1120 97. Ferrari MJ, Bansal S, Meyers LA, Björnstad ON. Network frailty and the geometry of herd  
1121 immunity. *Proc R Soc B Biol Sci.* 2006;273: 2743–2748.
- 1122 98. Newman MEJ. Spread of epidemic disease on networks. *Phys Rev E.* 2002;66: 016128.
- 1123 99. Durrett R. *Random Graph Dynamics.* Cambridge University Press; 2006.
- 1124 100. Britton T, Janson S, Martin-Löf A. Graphs with specified degree distributions, simple epidemics,  
1125 and local vaccination strategies. *Adv Appl Probab.* 2007;39: 922–948.
- 1126 101. Danon L, House TA, Read JM, Keeling MJ. Social encounter networks: Collective properties and  
1127 disease transmission. *J R Soc Interface.* 2012;9: 2826–2833.
- 1128 102. Danon L, Read JM, House TA, Vernon MC, Keeling MJ. Social encounter networks:  
1129 Characterizing Great Britain. *Proc R Soc B Biol Sci.* 2013; 20131037.
- 1130 103. World Health Organization. The First Few X (FFX) Cases and contact investigation protocol for  
1131 2019-novel coronavirus (2019-nCoV) infection. 2020. Available: [https://www.who.int/publications-](https://www.who.int/publications-detail-redirect/the-first-few-x-(ffx)-cases-and-contact-investigation-protocol-for-2019-novel-coronavirus-(2019-ncov)-infection)  
1132 [detail-redirect/the-first-few-x-\(ffx\)-cases-and-contact-investigation-protocol-for-2019-novel-](https://www.who.int/publications-detail-redirect/the-first-few-x-(ffx)-cases-and-contact-investigation-protocol-for-2019-novel-coronavirus-(2019-ncov)-infection)  
1133 [coronavirus-\(2019-ncov\)-infection](https://www.who.int/publications-detail-redirect/the-first-few-x-(ffx)-cases-and-contact-investigation-protocol-for-2019-novel-coronavirus-(2019-ncov)-infection)
- 1134 104. Black AJ, Geard N, McCaw JM, McVernon J, Ross J V. Characterising pandemic severity and  
1135 transmissibility from data collected during first few hundred studies. *Epidemics.* 2017;19: 61–73.

- 1136 105. Cauchemez S, Ferguson NM, Wachtel C, Tegnell A, Saour G, Duncan B, et al. Closure of schools  
1137 during an influenza pandemic. *Lancet Infect Dis.* 2009;9: 473–481.
- 1138 106. Cauchemez S, Valleron A-J, Boelle P-Y, Flahault A, Ferguson NM. Estimating the impact of  
1139 school closure on influenza transmission from sentinel data. *Nature.* 2008;452: 750–754.
- 1140 107. Davies NG, Klepac P, Liu Y, Prem K, Jit M, CMMID COVID-19 Working Group, et al. Age-  
1141 dependent effects in the transmission and control of COVID-19 epidemics. *Nat Med.* 2020.
- 1142 108. Viner RM, Russell SJ, Croker H, Packer J, Ward J, Stansfield C, et al. School closure and  
1143 management practices during coronavirus outbreaks including COVID-19: a rapid systematic  
1144 review. *Lancet Child Adolesc Heal.* 2020;4: 397–404.
- 1145 109. Cowling BJ, Ali ST, Ng TWY, Tsang TK, Li JCM, Fong MW, et al. Impact assessment of non-  
1146 pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an  
1147 observational study. *Lancet Public Heal.* 2020;4: 397–404.
- 1148 110. Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward JL, Hudson L, et al. Susceptibility to  
1149 and transmission of COVID-19 amongst children and adolescents compared with adults: a  
1150 systematic review and meta-analysis. *medRxiv.* 2020.
- 1151 111. Vogel G. How Sweden wasted a “rare opportunity” to study coronavirus in schools. 2020.  
1152 Available: [https://www.sciencemag.org/news/2020/05/how-sweden-wasted-rare-opportunity-study-](https://www.sciencemag.org/news/2020/05/how-sweden-wasted-rare-opportunity-study-coronavirus-schools)  
1153 [coronavirus-schools](https://www.sciencemag.org/news/2020/05/how-sweden-wasted-rare-opportunity-study-coronavirus-schools)
- 1154 112. McBryde ES, Trauer JM, Adekunle A, Ragonnet R, Meehan MT. Stepping out of lockdown should  
1155 start with school re-openings while maintaining distancing measures. *Insights from mixing*  
1156 *matrices and mathematical models.* *medRxiv.* 2020.
- 1157 113. Teslya A, Pham TM, Godijk NG, Kretzschmar ME, Bootsma MCJ, Rozhnova G. Impact of self-  
1158 imposed prevention measures and short-term government-imposed social distancing on mitigating  
1159 and delaying a COVID-19 epidemic: A modelling study. *PLoS Med.* 2020.
- 1160 114. Gilbert N. *Agent-based models.* 2nd Editio. Sage Publications Inc.; 2019.
- 1161 115. Squazzoni F, Polhill JG, Edmonds B, Ahrweiler P, Antosz P, Scholz G, et al. Computational  
1162 models that matter during a global pandemic outbreak: A call to action. *J Artif Soc Soc Simul.*  
1163 2020;23: 10.

- 1164 116. Bryce C, Ring P, Ashby S, Wardman JK. Resilience in the face of uncertainty: early lessons from  
1165 the COVID-19 pandemic. *J Risk Res.* 2020.
- 1166 117. Kandel N, Chungong S, Omaar A, Xing J. Health security capacities in the context of COVID-19  
1167 outbreak: an analysis of International Health Regulations annual report data from 182 countries.  
1168 *Lancet.* 2020;395: 1047–1053.
- 1169 118. Cohn S, Kutalek R. Historical parallels, Ebola virus disease and cholera: Understanding  
1170 community distrust and social violence with epidemics. *PLoS Curr.* 2016;8.
- 1171 119. Kalenga OI, Moeti M, Sparrow A, Nguyen VK, Lucey D, Ghebreyesus TA. The ongoing Ebola  
1172 epidemic in the Democratic Republic of Congo, 2018-2019. *N Engl J Med.* 2019;381: 373–383.
- 1173 120. Sanicas M, Forleo E, Pozzi G, Diop D. A review of the surveillance systems of influenza in  
1174 selected countries in the tropical region. *Pan Afr Med J.* 2014;19: 121.
- 1175 121. Sankoh O, Byass P. The INDEPTH network: Filling vital gaps in global epidemiology. *Int J*  
1176 *Epidemiol.* 2012;41: 579–588.
- 1177 122. Wilkinson A, Ali H, Bedford J, Boonyabancha S, Connolly C, Conteh A, et al. Local response in  
1178 health emergencies: key considerations for addressing the COVID-19 pandemic in informal urban  
1179 settlements. *Environ Urban.* 2020;1: 1–20.
- 1180 123. World Health Organization. Revealing the toll of COVID-19: A technical package for rapid mortality  
1181 surveillance and epidemic response. 2020. Available:  
1182 <https://www.who.int/publications/i/item/revealing-the-toll-of-covid-19>
- 1183 124. Kruk ME, Pate M, Mullan Z. Introducing The Lancet Global Health Commission on High-Quality  
1184 Health Systems in the SDG Era. *Lancet Glob Heal.* 2017;5: E480–E481.
- 1185 125. Quaife M, van Zandvoort K, Gimma A, Shah K, McCreesh N, Prem K, et al. The impact of COVID-  
1186 19 control measures on social contacts and transmission in Kenyan informal settlements.  
1187 *medRxiv.* 2020.
- 1188 126. Kelley M, Ferrand RA, Muraya K, Chigudu S, Molyneux S, Pai M, et al. An appeal for practical  
1189 social justice in the COVID-19 global response in low-income and middle-income countries.  
1190 *Lancet Glob Heal.* 2020;395: 1047–1053.
- 1191 127. University of Oxford Blavatnik School of Government. Coronavirus government response tracker.

- 1192 2020.
- 1193 128. Dong E. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis.*  
1194 2020;20: 533–534.
- 1195 129. Kenah E. Contact intervals, survival analysis of epidemic data, and estimation of  $R_0$ . *Biostatistics.*  
1196 2010;12: 548–566.
- 1197 130. Oliver N, Lepri B, Sterly H, Lambiotte R, Delataille S, De Nadai M, et al. Mobile phone data for  
1198 informing public health actions across the COVID-19 pandemic life cycle. *Sci Adv.* 2020;  
1199 eabc0764.
- 1200 131. Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus disease 2019  
1201 outbreak based on crowdsourced data: a population-level observational study. *Lancet Digit Heal.*  
1202 2020;2: e201–e208.
- 1203 132. Leclerc Q, Nightingale ES, Abbott S, CMMID nCoV Working Group, Jombart T. Analysis of  
1204 temporal trends in potential COVID-19 cases reported through NHS Pathways England. *medRxiv.*  
1205 2020.
- 1206 133. Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact surveys  
1207 and demographic data. *PLoS Comput Biol.* 2017;13: e1005697.
- 1208 134. Klepac P, Kissler S, Gog J. Contagion! The BBC Four Pandemic – The model behind the  
1209 documentary. *Epidemics.* 2018;24: 49–59.
- 1210 135. Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Report 9: Impact of  
1211 non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand.  
1212 2020. Available: [www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-9-  
1213 impact-of-npis-on-covid-19/](http://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-9-impact-of-npis-on-covid-19/)
- 1214 136. Dehning J, Zierenberg J, Spitzner EP, Wibral M, Neto JP, Wilczek M, et al. Inferring change points  
1215 in the spread of COVID-19 reveals the effectiveness of interventions. *Science (80- ).* 2020;  
1216 eabb9789.
- 1217 137. Gilbert M, Pullano G, Pinotti F, Valdano E, Poletto C, Boëlle PY, et al. Preparedness and  
1218 vulnerability of African countries against importations of COVID-19: a modelling study. *Lancet.*  
1219 2020;395.

- 1220 138. Kifer D, Bugada D, Villar-Garcia J, Gudelj I, Menni C, Sudre CH, et al. Effects of environmental  
1221 factors on severity and mortality of COVID-19. medRxiv. 2020.
- 1222 139. Al-Rousan N, Al-Najjar H. The correlation between the spread of COVID-19 infections and  
1223 weather variables in 30 Chinese provinces and the impact of Chinese government mitigation  
1224 plans. *Eur Rev Med Pharmacol Sci*. 2020;24: 4565–4571.
- 1225 140. Liu J, Zhou J, Yao J, Zhang X, Li L, Xu X, et al. Impact of meteorological factors on the COVID-19  
1226 transmission: A multi-city study in China. *Sci Total Environ*. 2020;726: 138513.
- 1227 141. Qi H, Xiao S, Shi R, Ward MP, Chen Y, Tu W, et al. COVID-19 transmission in Mainland China is  
1228 associated with temperature and humidity: A time-series analysis. *Sci Total Environ*. 2020;19:  
1229 138778.
- 1230 142. Şahin M. Impact of weather on COVID-19 pandemic in Turkey. *Sci Total Environ*. 2020;728:  
1231 138810.
- 1232 143. Menebo MM. Temperature and precipitation associate with Covid-19 new daily cases: A  
1233 correlation study between weather and Covid-19 pandemic in Oslo, Norway. *Sci Total Environ*.  
1234 2020;737: 139659.
- 1235 144. Tosepu R, Gunawan J, Effendy DS, Ahmad LOAI, Lestari H, Bahar H, et al. Correlation between  
1236 weather and Covid-19 pandemic in Jakarta, Indonesia. *Sci Total Environ*. 2020;4: 138436.
- 1237 145. Araujo MB, Naimi B. Spread of SARS-CoV-2 Coronavirus likely to be constrained by climate.  
1238 medRxiv. 2020.
- 1239 146. Coro G. A global-scale ecological niche model to predict SARS-CoV-2 coronavirus infection rate.  
1240 *Ecol Modell*. 2020;431: 109187.
- 1241 147. Carlson CJ, Chipperfield JD, Benito BM, Telford RJ, O'Hara RB. Species distribution models are  
1242 inappropriate for COVID-19. *Nat Ecol Evol*. 2020;4: 770–771.
- 1243 148. European Centre for Medium-Range Weather Forecasts. The ERA5 dataset. [cited 15 Jul 2020].  
1244 Available: <https://www.ecmwf.int/en/forecasts/datasets/reanalysis-datasets/era5>
- 1245 149. Hurrell JW, Holland MM, Gent PR, Ghan S, Kay JE, Kushner PJ, et al. The community earth  
1246 system model: A framework for collaborative research. *Bull Am Meteorol Soc*. 2013;94: 1339–60.
- 1247 150. Baker RE, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. Susceptible supply limits the role of

- 1248 climate in the early SARS-CoV-2 pandemic. *Science* (80- ). 2020;369: 315–319.
- 1249 151. Mecenas P, Bastos R, Vallinoto A, Normando D. Effects of temperature and humidity on the  
1250 spread of COVID-19: A systematic review. *medRxiv*. 2020.
- 1251 152. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan,  
1252 China, of novel coronavirus–infected pneumonia. *N Engl J Med*. 2020.
- 1253 153. De Angelis D, Presanis AM, Birrell PJ, Tomba GS, House T. Four key challenges in infectious  
1254 disease modelling using data from multiple sources. *Epidemics*. 2015;10: 83–87.
- 1255 154. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based  
1256 mitigation measures influence the course of the COVID-19 epidemic? *Lancet*. 2020;395: 931–934.
- 1257 155. Dawid AP. Prequential data analysis. *Current Issues in Statistical Inference: Essays in Honor of D*  
1258 *Basu*. 1992. pp. 113–126.
- 1259 156. Reich NG, McGowan CJ, Yamana TK, Tushar A, Ray EL, Osthus D, et al. Accuracy of real-time  
1260 multi-model ensemble forecasts for seasonal influenza in the U.S. *PLoS Comput Biol*. 2019;15:  
1261 e1007486.
- 1262 157. Shea BK, Runge MC, Pannell D, Probert WJM, Li SL, Tildesley M, et al. Harnessing multiple  
1263 models for outbreak management. *Science* (80- ). 2020;368: 577–579.
- 1264 158. Thompson RN, Gilligan CA, Cunniffe NJ. Control fast or control smart: When should invading  
1265 pathogens be controlled? *PLoS Comput Biol*. 2018;14.
- 1266 159. Zimmer C, Leuba SI, Cohen T, Yaesoubi R. Accurate quantification of uncertainty in epidemic  
1267 parameter estimates and predictions using stochastic compartmental models. *Stat Methods Med*  
1268 *Res*. 2019; 3591–3608.
- 1269 160. Chowell G. Fitting dynamic models to epidemic outbreaks with quantified uncertainty: A primer for  
1270 parameter uncertainty, identifiability, and forecasts. *Infect Dis Model*. 2017;2: 379–398.
- 1271 161. Shearer FM, Moss R, McVernon J, Ross J V, McCaw JM. Infectious disease pandemic planning  
1272 and response: Incorporating decision analysis. *PLoS Med*. 2020;17: e1003018.
- 1273 162. Lipsitch M, Finelli L, Heffernan RT, Leung GM, Redd SC. Improving the evidence base for  
1274 decision making during a pandemic: The example of 2009 influenza A/H1N1. *Biosecurity*  
1275 *Bioterrorism Biodefense Strateg Pract Sci*. 2011;9: 89–115.

- 1276 163. Lipsitch M, Donnelly CA, Fraser C, Blake IM, Cori A, Dorigatti I, et al. Potential biases in  
1277 estimating absolute and relative case-fatality risks during outbreaks. *PLoS Negl Trop Dis.* 2015;9:  
1278 e0003846.
- 1279 164. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of  
1280 coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis.* 2020;20: 669–677.

1281

1282

**1283 Acknowledgements**

1284 The authors would like to thank the Isaac Newton Institute for Mathematical Sciences,  
1285 Cambridge ([www.newton.ac.uk](http://www.newton.ac.uk)), for support during the virtual “Infectious Dynamics of  
1286 Pandemics” programme where work on this paper was begun. This work was undertaken in part  
1287 as a contribution to the “Rapid Assistance in Modelling the Pandemic” initiative coordinated by  
1288 the Royal Society. Thanks to Sam Abbott for helpful comments about the original manuscript.

1289

**1290 Funding**

1291 This work was supported by the Isaac Newton Institute (EPSRC grant number EP/R014604/1).  
1292 RNT thanks Christ Church (Oxford) for funding via a Junior Research Fellowship. RNT and SF  
1293 acknowledge support from the Wellcome Trust (210758/Z/18/Z). LHKC acknowledges support  
1294 from the BBSRC (BB/R009236/1). BA is supported by the Natural Environment Research  
1295 Council (NE/N014979/1). CAD and KVP thank the UK MRC and DFID for centre funding  
1296 (MR/R015600/1). CAD also thanks the UK NIHR (National Institute for Health Research)  
1297 HPRU (Health Protection Research Unit). RME acknowledges HDR UK (MR/S003975/1) and  
1298 the UK MRC (MC\_PC 19065). HH and MEK acknowledge support from the Netherlands  
1299 Organisation for Health Research and Development (ZonMw; grant 10430022010001). TH  
1300 acknowledges support from the Royal Society (INF\R2\180067) and the Alan Turing Institute for

1301 Data Science and Artificial Intelligence. MK and MJT acknowledge support from the UK MRC  
1302 (MR/V009761/1). IZK acknowledges support from the Leverhulme Trust (RPG-2017-370).  
1303 MEK acknowledges support from the Netherlands Organisation for Health Research and  
1304 Development (ZonMw; grant 91216062). JCM acknowledges startup funding from La Trobe  
1305 University. CABP acknowledges funding of the NTD Modelling Consortium by the Bill and  
1306 Melinda Gates Foundation (OPP1184344). LP acknowledges support from the Wellcome Trust  
1307 and the Royal Society (202562/Z/16/Z). JRCP acknowledges support from the South African  
1308 Centre for Epidemiological Modelling and Analysis (SACEMA), a Department of Science and  
1309 Innovation-National Research Foundation Centre of Excellence hosted at Stellenbosch  
1310 University. CJS acknowledges support from CNPq and FAPERJ. PT acknowledges support from  
1311 Vetenskapsrådet Swedish Research Council (2016-04566).

1312

1313 **Ethics statement**

1314 The authors declare that no ethical concerns exist.

1315

1316 **Data accessibility statement**

1317 Data sharing is not applicable to this manuscript as no new data were created or analysed in this  
1318 study.

1319

1320 **Competing interests statement**

1321 The authors declare that no competing interests exist.

1322

1323 **Authors' contributions**

1324 RNT, TDH, VI, HH, DM and OR organised the workshop and designed the study. All authors  
1325 attended the workshop, contributed to discussions and wrote sections of the manuscript. RNT  
1326 compiled the manuscript. All authors edited the manuscript and approved the final version for  
1327 publication.